Premier Graphene (BIEI) S-1/A 16 Oct 17 IPO registration (amended) Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jun. 30, 2017
Document And Entity Information
Entity Registrant Name	PREMIER BIOMEDICAL INC
Entity Central Index Key	1,515,740
Document Type	S1
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Document Fiscal Year Focus	2,017

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash	$ 125,341	$ 22,437	$ 35,414
Prepaid Expenses		11,430	9,166
Other current assets	141,521	11,430
Total current assets	266,862	33,867	44,580
Property and equipment, net	6,603	5,100	3,647
Total assets	273,465	38,967	48,227
Current liabilities:
Accounts Payable	163,087	220,740	188,265
Accounts payable, related parties	53,436	52,489	54,668
Accrued interest		18,026	7,792
Accrued interest, related parties	4,770	3,570	1,170
Convertible notes payable, net of discounts of $-0- and $149,456 at June 30, 2017 and December 31, 2016, respectively		153,024	41,815
Notes payable, related parties	30,000	30,000	30,000
Derivative liabilities	6,253,880	221,822	150,076
Total current liabilities	6,505,173	699,671	473,786
Total liabilities	6,505,173	699,671	473,786
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 2,000,000 and -0- shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively	2,000	2,000
Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 522,155,037 and 304,556,650 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively	5,222	3,046	823
Additional paid in capital	12,902,891	11,899,504	10,370,651
Accumulated deficit	(19,141,821)	(12,565,254)	(10,797,033)
Total stockholders' equity (deficit)	(6,231,708)	(660,704)	(425,559)	$ (67,759)
Total liabilities and stockholders' equity (deficit)	$ 273,465	$ 38,967	$ 48,227

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Current liabilities:
Convertible notes payable, net of discounts	$ 0	$ 149,456	$ 246,185
Stockholders' equity (deficit):
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, authorized shares	10,000,000	10,000,000	10,000,000
Preferred stock, issued shares	2,000,000	2,000,000	0
Preferred stock, outstanding shares	2,000,000	2,000,000	0
Common stock, par value	$ 0.00001	$ 0.00001	$ 0.00001
Common stock, authorized shares	1,000,000,000	1,000,000,000	1,000,000,000
Common stock, issued shares	522,155,037	304,556,650	82,331,062
Common stock, outstanding shares	522,155,037	304,556,650	82,331,062

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Statements Of Operations
Revenue
Operating expenses:
Research and development		113,862	234,095
General and administrative	73,305	191,379	133,289
Professional fees	86,756	332,650	2,015,898
Total operating expenses	160,061	637,891	2,383,282
Net operating loss	(160,061)	(637,891)	(2,383,282)
Other income (expense):
Interest expense	(153,347)	(817,423)	(198,049)
Other expense
Loss on judgment, Typenex		(340,647)
Gain on settlement, Typenex		53,788
Equity in losses of investment in joint venture	(2,058)
Change in derivative liabilities	(6,261,101)	(26,048)	(20,076)
Total other income (expenses)	(6,416,506)	(1,130,330)	(218,125)
Net loss	$ (6,576,567)	$ (1,768,221)	$ (2,601,407)
Weighted average number of common shares outstanding - basic and fully diluted	452,007,980	151,651,420	31,264,255
Net loss per share - basic and fully diluted	$ (0.01)	$ (0.01)	$ (0.08)

STATEMENT OF STOCKHOLDERS' EQUI

STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 31, 2014		$ 218	$ 8,127,649	$ (8,195,626)	$ (67,759)
Beginning Balance, Shares at Dec. 31, 2014		21,757,175
Amortization of warrants granted for services, related parties			1,529,182		1,529,182
Amortization of warrants granted for services			319,986		319,986
Beneficial conversion feature of convertible note			167,011		167,011
Common stock issued on debt conversions, Amount		$ 567	226,821		227,388
Common stock issued on debt conversions, Shares		56,723,887
Exercise of warrants at $0.00001 per share, related party, Amount		$ 40			40
Exercise of warrants at $0.00001 per share, related party, Shares		4,000,000
Common stock cancelled, Amount		$ (2)	2
Common stock cancelled, Shares		(150,000)
Shares issued for services, Amount
Net loss				(2,601,407)	(2,601,407)
Ending Balance, Amount at Dec. 31, 2015		$ 823	10,370,651	(10,797,033)	(425,559)
Ending Balance, Shares at Dec. 31, 2015		82,331,062
Shares issued for services, Amount					58,800
Beginning Balance, Amount at Dec. 31, 2015		$ 823	10,370,651	(10,797,033)	(425,559)
Beginning Balance, Shares at Dec. 31, 2015		82,331,062
Amortization of warrants granted for services, related parties			25,030		25,030
Amortization of warrants granted for services			14,739		14,739
Common stock issued on debt conversions, Amount		$ 1,652	736,064		737,716
Common stock issued on debt conversions, Shares		165,196,985
Exercise of warrants at $0.00001 per share, related party, Amount		$ 200			200
Exercise of warrants at $0.00001 per share, related party, Shares		20,000,000
Common stock issued on equity line of credit, Amount		$ 280	143,240		143,520
Common stock issued on equity line of credit, Shares		27,952,890
Exercise of preferred stock warrants at $0.001 per share, related parties, Amount	$ 2,000				2,000
Exercise of preferred stock warrants at $0.001 per share, related parties, Shares	2,000,000
Exercise of cashless warrants at $0.00001 per share, Amount		$ 22	(22)
Exercise of cashless warrants at $0.00001 per share, Shares		2,248,846
Shares issued for serttlement of reimbursements, related party, Amount		$ 6	13,759		13,765
Shares issued for serttlement of reimbursements, related party, Shares		600,000
Shares issued for services, Amount		$ 63	70,558		70,621
Shares issued for services, Shares		6,226,867
Adjustments to derivative liability due to debt conversions			525,485		525,485
Net loss				(1,768,221)	(1,768,221)
Ending Balance, Amount at Dec. 31, 2016	$ 2,000	$ 3,046	$ 11,899,504	$ (12,565,254)	(660,704)
Ending Balance, Shares at Dec. 31, 2016	2,000,000	304,556,650
Shares issued for services, Amount
Net loss					(6,576,567)
Ending Balance, Amount at Jun. 30, 2017					$ (6,231,708)

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (6,576,567)	$ (1,768,221)	$ (2,601,407)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,191	2,083	1,462
Equity in profit of joint venture investment	2,058
Change in fair market value of derivative liabilities	6,261,101	26,048	20,076
Amortization of debt discounts	149,456	749,162	175,707
Gain on settlement of judgment		(53,788)
Stock based compensation, related parties		25,030	1,529,182
Stock based compensation		85,360	319,986
Decrease (increase) in assets:
Other current assets	(130,091)
Prepaid expenses		(2,264)	284
Increase (decrease) in liabilities:
Accounts payable	(57,653)	32,475	40,774
Accounts payable, related parties	947	11,586	29,369
Accrued interest	2,691	65,860	21,172
Accrued interest, related parties	1,200	2,400	1,170
Judgment payable		340,647
Net cash used in operating activities	(345,667)	(483,622)	(462,225)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(2,694)	(3,536)
Investment in joint venture	(2,058)
Net cash used in investing activities	(4,752)	(3,536)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of stock, net of offering costs	435,000
Proceeds from exercise of warrants, related party		2,200	40
Proceeds from sale of stock on equity line of credit	18,323	143,520
Proceeds of convertible notes payable		417,500	365,000
Proceeds of notes payable, related parties			30,000
Repayments of convertible notes payable		(89,039)
Net cash provided by financing activities	453,323	474,181	395,040
NET CHANGE IN CASH	102,904	(12,977)	(67,185)
CASH AT BEGINNING OF PERIOD	22,437	35,414	102,599
CASH AT END OF PERIOD	125,341	22,437	35,414
SUPPLEMENTAL INFORMATION:
Interest paid		13,539
Income taxes paid
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Discount on beneficial conversion feature on convertible note			167,011
Value of debt discounts		571,183	130,000
Value of derivative adjustment due to debt conversions	229,043	525,485
Value of shares issued for conversion of debt	323,197	737,716	227,388
Convertible note issued in settlement of judgment payable		300,000
Common stock issued for settlement of accounts payable, related party		13,765
Cashless exercise of common stock warrants, 2,250,000 warrants exercised		$ 22

Nature of Business and Signific

Nature of Business and Significant Accounting Policies	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
Note 1 - Nature of Business and Significant Accounting Policies	Basis of Presentation The accompanying unaudited, condensed financial statements of Premier Biomedical, Inc. (“the Company”) have been prepared pursuant to rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, these statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. It is suggested that these statements be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. Equity Method Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an Investee depends on an evaluation of several factors including, among others, representation on the Investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the Investee company. Under the equity method of accounting, an Investee company’s accounts are not reflected within the Company’s Balance Sheets and Statements of Operations; however, the Company’s share of the earnings or losses of the Investee company is reflected in the caption “Equity in losses of unconsolidated entity” in the Statements of Operations. The Company’s carrying value in an equity method Investee company is typically reflected in the caption “Investment in Joint Venture.” in the Company’s Balance Sheets. As of June 30, 2017, our share of losses from the investee company exceeded our basis, therefore the investment is not currently presented on the balance sheet. U.S. GAAP considers a change in reporting entity to include “changing specific subsidiaries that make up the group of entities for which consolidated financial statements are presented.” Circumstances may arise where a parent’s controlling financial interest (e.g., generally an ownership interest in excess of 50 percent of the outstanding voting stock) is reduced to a noncontrolling investment that still enables it to exercise significant influence over the operating and financial policies of the investee. A change that results from changed facts and circumstances (such as a partial sale of a subsidiary), where there was only one acceptable method of accounting prior to the change in circumstances (consolidation) and only one acceptable method of accounting after the change (equity method accounting), is not a change in reporting entity and is not be accounted for retrospectively. Accordingly, a change from a controlling interest to a noncontrolling investment accounted for under the equity method is accounted for prospectively from the date of change in control. When the Company’s carrying value in an equity method Investee company is reduced to zero, no further losses are recorded in the Company’s consolidated financial statements unless the Company guaranteed obligations of the Investee company or has committed additional funding. When the Investee company subsequently reports income, the Company will not record its share of such income until it equals the amount of its share of losses not previously recognized. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents We maintain cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Patent Rights and Applications Patent rights and applications costs include the acquisition costs and costs incurred for the filing of patents. Patent rights and applications are amortized on a straight-line basis over the legal life of the patent rights beginning at the time the patents are approved. Patent costs for unsuccessful patent applications are expensed when the application is terminated. Fair Value of Financial Instruments Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, prepaid expenses and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments. Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share. Stock-Based Compensation Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company’s stock based compensation consisted of the following during the six months ended June 30, 2017 and 2016, respectively: June 30, June 30, 2017 2016 Common stock issued for services $ - $ 58,800 Warrants issued for services, related parties - 13,014 Warrants issued for services - 17,066 Total stock based compensation $ - $ 88,880 Revenue Recognition Sales on fixed price contracts are recorded when services are earned, the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue from sales in which payment has been received, but the earnings process has not occurred. Sales have not yet commenced, other than sales through our joint venture, which our recognized by our joint venture upon shipment of goods, which are paid for at the time of order. Advertising and Promotion All costs associated with advertising and promoting products are expensed as incurred. These expenses were $25,413 and $51,710 for the six months ended June 30, 2017 and 2016, respectively. Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations. Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions. Recent Accounting Pronouncements In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350) In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business No other new accounting pronouncements, issued or effective during the six months ended June 30, 2017, have had or are expected to have a significant impact on the Company’s financial statements.	Nature of Business Premier Biomedical, Inc. (“the Company”) was incorporated in the State of Nevada on May 10, 2010 (“Inception”). The Company was formed to develop and market medications and procedures that address a significant number of the most highly visible health issues currently affecting mankind. The Company will market these medications and procedures to leading worldwide pharmaceutical firms via publication in medical journals and by direct contact. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents We maintain cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Patent Rights and Applications Patent rights and applications costs include the acquisition costs and costs incurred for the filing of patents. Patent rights and applications are amortized on a straight-line basis over the legal life of the patent rights beginning at the time the patents are approved. Patent costs for unsuccessful patent applications are expensed when the application is terminated. Fair Value of Financial Instruments Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, prepaid expenses and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments. Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share. Stock-Based Compensation Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company’s stock based compensation consisted of the following during the years ended December 31, 2016 and 2015, respectively: December 31, December 31, 2016 2015 Common stock issued for services $ 70,621 $ - Warrants issued for services, related parties 25,030 1,529,182 Warrants issued for services 14,739 319,986 Total stock based compensation $ 110,390 $ 1,849,168 Revenue Recognition Sales on fixed price contracts are recorded when services are earned, the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue from sales in which payment has been received, but the earnings process has not occurred. Sales have not yet commenced. Advertising and Promotion All costs associated with advertising and promoting products are expensed as incurred. These expenses were $82,246 and $59,956 for the years ended December 31, 2016 and 2015, respectively. Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations. Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions. Recently Issued Accounting Pronouncements In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350) In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business In December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers Revenue from Contracts with Customers In October 2016, the FASB issued ASU No. 2016-17, Consolidation (Topic 810): Interests Held through Related Parties that are under Common Control In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory In August, 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In June, 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718) . In March, 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date In March, 2016, the FASB issued ASU No. 2016-07, Investments—Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. In March, 2016, the FASB issued ASU No. 2016-04, Liabilities—Extinguishments of Liabilities (Subtopic 405-20): Recognition of Breakage for Certain Prepaid Stored-Value Products No other new accounting pronouncements, issued or effective during the year ended December 31, 2016, have had or are expected to have a significant impact on the Company’s financial statements.

Going Concern

Going Concern	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
Note 2 - Going Concern	As shown in the accompanying financial statements, the Company has no revenues, incurred net losses from operations resulting in an accumulated deficit of $19,141,821, and had negative working capital of ($6,238,311) at June 30, 2017. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company is currently seeking additional sources of capital to fund short term operations. The Company, however, is dependent upon its ability to secure equity and/or debt financing and there are no assurances that the Company will be successful; therefore, without sufficient financing it would be unlikely for the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. The financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.	As shown in the accompanying financial statements, the Company has no revenues, incurred net losses from operations resulting in an accumulated deficit of $12,565,254, and had negative working capital of ($665,804) at December 31, 2016. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management is actively pursuing new products and services to begin generating revenues. In addition, the Company is currently seeking additional sources of capital to fund short term operations. The Company, however, is dependent upon its ability to secure equity and/or debt financing and there are no assurances that the Company will be successful; therefore, without sufficient financing it would be unlikely for the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. The financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Restatement

Restatement	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
Note 3 - Restatement	The Company is restated its December 31, 2015 financial statements and is restating the interim financial statements for the three months ended March 31, 2016, the six months ended June 30, 2016 and nine months ended September 30, 2016 in order to account for embedded derivatives within the Redwood Notes, rather than beneficial conversion feature discounts. The financial statements will be restated prospectively during 2017. The Company determined that it had not properly recognized embedded derivative liabilities within the Redwood Notes that originated on various dates between December 28, 2015 and May 27, 2016. The Company has recognized a derivative liability in lieu of the previously recognized beneficial conversion feature and the related change in derivative liabilities and amortization of the debt discount expenses have been adjusted to correct this error. The following adjustments were made to the June 30, 2016 Restated Balance Sheet: PREMIER BIOMEDICAL, INC. BALANCE SHEET As Originally Reported As Restated June 30, June 30, 2016 Adjustments 2016 ASSETS Current assets: Cash $ 38,588 $ - $ 38,588 Prepaid expenses 11,545 - 11,545 Total current assets 50,133 - 50,133 Property and equipment, net 6,157 - 6,157 Total assets $ 56,290 $ - $ 56,290 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 143,703 $ - $ 143,703 Accounts payable, related parties 51,298 - 51,298 Accrued interest 22,079 - 22,079 Accrued interest, related parties 2,370 - 2,370 Judgment payable 340,647 - 340,647 Convertible notes payable, net of discounts of $334,869 210,548 (27,283 ) 183,265 Notes payable, related parties 30,000 - 30,000 Derivative liabilities - 507,352 507,352 Total current liabilities 800,645 480,069 1,280,714 Total liabilities 800,645 480,069 1,280,714 Commitments and contingencies - - - Stockholders' equity (deficit): Preferred stock, $0.001 par value, 10,000,000 shares authorized, 2,000,000 shares issued and outstanding 2,000 - 2,000 Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 125,714,852 shares issued and outstanding 1,257 - 1,257 Additional paid in capital 11,167,420 (383,637 ) 10,783,783 Accumulated deficit (11,915,032 ) (96,432 ) (12,011,464 ) Total stockholders' equity (deficit) (744,355 ) (480,069 ) (1,224,424 ) Total liabilities and stockholders' equity (deficit) $ 56,290 $ - $ 56,290 The following adjustments were made to the Six Months Ended June 30, 2016 Restated Statement of Operations: PREMIER BIOMEDICAL, INC. STATEMENT OF OPERATIONS As Originally Reported As Restated June 30, June 30, 2016 Adjustments 2016 Revenue $ - $ - $ - Operating expenses: Research and development 59,686 - 59,686 General and administrative 91,466 - 91,466 Professional fees 225,959 - 225,959 Total operating expenses 377,111 - 377,111 Net operating loss (377,111 ) - (377,111 ) Other expense: Interest expense (419,477 ) 10,666 (408,811 ) Other expense (340,647 ) - (340,647 ) Change in derivative liabilities - (87,862 ) (87,862 ) Total other expenses (760,124 ) (77,196 ) (837,320 ) Net loss $ (1,137,235 ) $ (77,196 ) $ (1,214,431 ) The following adjustments were made to the Three Months Ended June 30, 2016 Restated Statement of Operations: PREMIER BIOMEDICAL, INC. STATEMENT OF OPERATIONS As Originally Reported As Restated June 30, June 30, 2016 Adjustments 2016 Revenue $ - $ - $ - Operating expenses: Research and development 49,545 - 49,545 General and administrative 41,981 - 41,981 Professional fees 87,511 - 87,511 Total operating expenses 179,037 - 179,037 Net operating loss (179,037 ) - (179,037 ) Other expense: Interest expense (202,402 ) (33,122 ) (235,524 ) Other expense (340,647 ) - (340,647 ) Change in derivative liabilities - (189,191 ) (189,191 ) Total other expenses (543,049 ) (222,313 ) (765,362 ) Net loss $ (722,086 ) $ (222,313 ) $ (944,399 ) The following adjustments were made to the June 30, 2016 Restated Statement of Cash Flows: PREMIER BIOMEDICAL, INC. STATEMENT OF CASH FLOWS As Originally Reported As Restated June 30, June 30, 2016 Adjustments 2016 CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ (1,137,235 ) $ (77,196 ) $ (1,214,431 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 1,026 - 1,026 Change in fair market value of derivative liabilities - 87,862 87,862 Amortization of debt discounts 383,229 (10,666 ) 372,563 Stock based compensation, related parties 13,014 - 13,014 Stock based compensation 75,866 - 75,866 Decrease (increase) in assets: Prepaid expenses (2,379 ) - (2,379 ) Increase (decrease) in liabilities: Accounts payable (44,562 ) - (44,562 ) Accounts payable, related parties 10,395 - 10,395 Accrued interest 35,048 - 35,048 Accrued interest, related parties 1,200 - 1,200 Judgment payable 340,647 - 340,647 Net cash used in operating activities (323,751 ) - (323,751 ) CASH FLOWS FROM INVESTING ACTIVITIES Purchases of property and equipment (3,536 ) - (3,536 ) Net cash used in investing activities (3,536 ) - (3,536 ) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from exercise of warrants, related party 2,000 - 2,000 Proceeds from convertible notes payable 417,500 - 417,500 Repayments from convertible notes payable (89,039 ) - (89,039 ) Net cash provided by financing activities 330,461 - 330,461 NET CHANGE IN CASH 3,174 - 3,174 CASH AT BEGINNING OF PERIOD 35,414 - 35,414 CASH AT END OF PERIOD $ 38,588 $ - $ 38,588 SUPPLEMENTAL INFORMATION: Interest paid $ 13,539 $ - $ 13,539 Income taxes paid $ - $ - $ - NON-CASH INVESTING AND FINANCING ACTIVITIES: Discount on beneficial conversion feature on convertible note $ 364,220 $ (364,220 ) $ - Value of debt discounts $ - $ 110,583 $ 110,583 Value of shares issued for conversion of debt $ 200,338 $ - $ 200,338 Cashless exercise of common stock warrants $ 22 $ - $ 22 Common stock issued for settlement of accounts payable $ 13,765 $ - $ 13,765	The Company is restating its December 31, 2015 financial statements and the interim financial statements for the three months ended March 31, 2016, the six months ended June 30, 2016 and nine months ended September 30, 2016 in order to account for embedded derivatives within the Redwood Notes, rather than beneficial conversion feature discounts. The financial statements will be restated prospectively during 2017. The Company determined that it had not properly recognized embedded derivative liabilities within the Redwood Notes that originated on various dates between December 28, 2015 and May 27, 2016. The Company has recognized a derivative liability in lieu of the previously recognized beneficial conversion feature and the related change in derivative liabilities and amortization of the debt discount expenses have been adjusted to correct this error. The following adjustments were made to the December 31, 2015 Restated Balance Sheet: PREMIER BIOMEDICAL, INC. BALANCE SHEET As Originally Reported As Restated December 31, December 31, 2015 Adjustments 2015 ASSETS Current assets: Cash $ 35,414 $ - $ 35,414 Prepaid expenses 9,166 - 9,166 Total current assets 44,580 - 44,580 Property and equipment, net 3,647 - 3,647 Total assets $ 48,227 $ - $ 48,227 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 188,265 $ - $ 188,265 Accounts payable, related parties 54,668 - 54,668 Accrued interest 7,792 - 7,792 Accrued interest, related parties 1,170 - 1,170 Convertible notes payable, net of discounts of $245,345 42,655 (840 ) 41,815 Notes payable, related parties 30,000 - 30,000 Derivative liabilities - 150,076 150,076 Total current liabilities 324,550 149,236 473,786 Total liabilities 324,550 149,236 473,786 Commitments and contingencies - - - Stockholders' equity (deficit): Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 82,331,062 and 21,757,175 shares issued and outstanding at December 31, 2015 and 2014, respectively Additional paid in capital 10,500,651 (130,000 ) 10,370,651 Accumulated deficit (10,777,797 ) (19,236 ) (10,797,033 ) Total stockholders' equity (deficit) (276,323 ) (149,236 ) (425,559 ) Total liabilities and stockholders' equity (deficit) $ 48,227 $ - $ 48,227 The following adjustments were made to the December 31, 2015 Restated Statement of Operations: PREMIER BIOMEDICAL, INC. STATEMENT OF OPERATIONS As Originally Reported As Restated December 31, December 31, 2015 Adjustments 2015 Revenue $ - $ - $ - Operating expenses: Research and development 234,095 - 234,095 General and administrative 133,289 - 133,289 Professional fees 2,015,898 - 2,015,898 Total operating expenses 2,383,282 - 2,383,282 Net operating loss (2,383,282 ) - (2,383,282 ) Other expense: Interest expense (198,889 ) 840 (198,049 ) Change in derivative liabilities - (20,076 ) (20,076 ) Total other expenses (198,889 ) (19,236 ) (218,125 ) Net loss $ (2,582,171 ) $ (19,236 ) $ (2,601,407 ) The December 31, 2015 Statement of Stockholders’ Equity (Deficit) was restated to increase the Accumulated Deficit from $10,777,797 to $10,797,033 for the additional net loss for the year of $19,236. The net loss as originally stated was $2,582,171, and as restated amounted to a net loss of $2,601,407. Additional Paid-In Capital was also restated to remove a $130,000 beneficial conversion feature from Additional Paid-In Capital that was corrected to be accounted for as an embedded derivative. The impact of the correction is summarized below: PREMIER BIOMEDICAL, INC. SUMMARY OF CORRECTIONS TO STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) As Originally Reported As Restated December 31, December 31, 2015 Adjustments 2015 Beneficial conversion feature of convertible note $ 297,011 $ (130,000 ) $ 167,011 Additional Paid-In Capital $ 10,500,651 $ (130,000 ) $ 10,370,651 Net loss for the year ended December 31, 2015 $ (2,582,171 ) $ (19,236 ) $ (2,601,407 ) Accumulated Deficit $ (10,777,797 ) $ (19,236 ) $ (10,797,033 ) The following adjustments were made to the December 31, 2015 Restated Statement of Cash Flows: PREMIER BIOMEDICAL, INC. STATEMENT OF CASH FLOWS As Originally Reported As Restated December 31, December 31, 2015 Adjustments 2015 CASH FLOWS FROM OPERATING ACTIVITIES Net (loss) $ (2,582,171 ) $ (19,236 ) $ (2,601,407 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 1,462 - 1,462 Change in fair market value of derivative liabilities - 20,076 20,076 Amortization of debt discounts 176,547 (840 ) 175,707 Stock based compensation, related parties 1,529,182 - 1,529,182 Stock based compensation 319,986 - 319,986 Decrease (increase) in assets: Prepaid expenses 284 - 284 Increase (decrease) in liabilities: Accounts payable 40,774 - 40,774 Accounts payable, related parties 29,369 - 29,369 Accrued interest 21,172 - 21,172 Accrued interest, related parties 1,170 - 1,170 Net cash used in operating activities (462,225 ) - (462,225 ) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from exercise of warrants, related party 40 - 40 Proceeds from convertible notes payable 365,000 - 365,000 Proceeds from notes payable, related parties 30,000 - 30,000 Net cash provided by financing activities 395,040 - 395,040 NET CHANGE IN CASH (67,185 ) - (67,185 ) CASH AT BEGINNING OF PERIOD 102,599 - 102,599 CASH AT END OF PERIOD $ 35,414 $ - $ 35,414 SUPPLEMENTAL INFORMATION: Interest paid $ - $ - $ - Income taxes paid $ - $ - $ - NON-CASH INVESTING AND FINANCING ACTIVITIES: Discount on beneficial conversion feature on convertible note $ 297,011 $ (130,000 ) $ 167,011 Value of debt discounts $ - $ 130,000 $ 130,000 Value of shares issued for conversion of debt $ 227,388 $ - $ 227,388

Related Party

Related Party	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
Note 4 - Related Party	Other Receivable The Company advanced a total of $48,778 to its joint venture partner, Premier Biomedical Pain Management Solutions, LLC, as of June 30, 2017. The advance was subsequently repaid on July 5, 2017. Accounts Payable The Company owed $46,016 and $46,016 as of June 30, 2017 and December 31, 2016, respectively, to entities owned by the Chairman of the Board of Directors. The amounts are related to patent costs and reimbursable expenses paid by the Chairman on behalf of the Company. The Company owed $1,192 and $306 as of June 30, 2017 and December 31, 2016, respectively, to the Company’s CEO for reimbursable expenses. The Company owed $6,228 and $6,167 as of June 30, 2017 and December 31, 2016, respectively, amongst members of the Company’s Board of Directors for reimbursable expenses. Notes Payable On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s CEO. On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s Chairman of the Board. On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from one of the Company’s Directors. Accrued interest of $4,770 was outstanding on these notes as of June 30, 2017.	Accounts Payable The Company owed $46,016 and $37,486 as of December 31, 2016 and 2015, respectively, to entities owned by the Chairman of the Board of Directors. The amounts are related to patent costs paid by the Chairman on behalf of the Company. The Company owed $306 and $3,265 as of December 31, 2016 and 2015, respectively, to the Company’s CEO for reimbursable expenses. The Company owed $6,167 and $13,917 as of December 31, 2016 and 2015, respectively, amongst members of the Company’s Board of Directors for reimbursable expenses. Notes Payable On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s CEO. On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s Chairman of the Board. On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from one of the Company’s Directors. Accrued interest of $3,570 was outstanding on these notes as of December 31, 2016. Preferred Stock Issuances for Exercise of Preferred Stock Warrants On January 29, 2016, the Company issued 1,000,000 shares of series A preferred stock pursuant to the exercise of warrants by the Company’s CEO at $0.001 per share for total proceeds of $1,000. On January 29, 2016, the Company issued 1,000,000 shares of series A preferred stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.001 per share for total proceeds of $1,000. Common Stock Warrants Exercised On October 19, 2016, the Company issued 4,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s CEO at $0.00001 per share for total proceeds of $40. On October 19, 2016, the Company issued 4,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.00001 per share for total proceeds of $40. On October 1, 2015, the Company issued 3,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.00001 per share for total proceeds of $30. On September 10, 2015, the Company issued 1,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.00001 per share for total proceeds of $10. Common Stock Warrants On October 7, 2015, the Company granted warrants to the following officers and directors, which will allow them to purchase shares of our common stock in the amounts indicated: William Hartman (1,000,000 shares); Mitchell Felder (1,000,000 shares), Heidi Carl (750,000 shares), John Borza (600,000 shares), Richard Najarian (200,000 shares), and Jay Rosen (200,000 shares). The exercise price of the foregoing warrants is five cents ($0.05) per share. The warrants are exercisable over ten (10) years. The total fair value of the 3,750,000 common stock warrants using the Black-Scholes option-pricing model is $31,109, or $0.0083 per share, based on a volatility rate of 232%, a risk-free interest rate of 1.75% and an expected term of 10.0 years, and is being amortized over the implied service term, or vesting period, of the warrants. One half of the shares underlying each of the respective warrants vest on June 15, 2016, with the balance vesting on December 15, 2016. In order for the warrants to vest on each of the foregoing dates, however, the holders must be serving in the same capacity on behalf of the Company as he or she was serving on October 21, 2015. The issuance of the warrants was fully approved by our Board of Directors on October 21, 2015, the date a fully executed resolution authorizing the issuance was delivered. The issuances were exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, the investors are sophisticated and familiar with our operations, and there was no solicitation in connection with the issuance. A total of $25,030 and $1,529,182 of previously issued warrants were amortized and expensed to professional fees as stock-based compensation during the years ended December 31, 2016 and 2015, respectively. Common Stock Issuances for Settlement of Accounts Payments On March 28, 2016, upon the resignation of Richard Najarian as one of the members of our Board of Directors, the Company issued 600,000 shares of common stock to Mr. Najarian in settlement of $13,765 of outstanding expense reimbursements. The total fair value of the common stock was $9,120 based on the closing price of the Company’s common stock on the date of grant.

Patent Rights and Applications

Patent Rights and Applications	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
Note 5 - Patent Rights and Applications	The Company amortizes its patent rights and applications on a straight line basis over the expected useful technological or economic life of the patents, which is typically 17 years from the legal approval of the patent applications when there is probable future economic benefits associated with the patent. The Company has elected to expense all of their patent rights and application costs due to difficulties associated with having to prove the value of their future economic benefits. All patent applications are currently pending and the Company has no patents that have yet been approved. It is the Company’s policy that it performs reviews of the carrying value of its patent rights and applications on an annual basis. On March 4, 2015, we entered into a Patent License Agreement (“PLA”) with the University of Texas at El Paso (“UTEP”) regarding our joint research and development of CTLA-4 Blockade with Metronomic Chemotherapy for the Treatment of Breast Cancer. This is the first PLA with UTEP following our Collaborative Agreement with them dated May 9, 2012, and memorializes the joint ownership of the applicable patent and the financial and other terms related thereto. On June 19, 2015, we entered into Amendment No. 1 to this Agreement, pursuant to which we explicitly included Provisional Patent Application No. 62/161,116 entitled, “Anti-CTLA-4 Blockade” (the “Application”) under the definition of “Patent Rights” as set forth in the PLA. The Application was filed with the United States Patent and Trademarks Office on May 13, 2015; the underlying technology was invented by Robert Kirken and Georgialina Rodriguez, and is solely-owned by The Board of Regents of The University of Texas System.	The Company amortizes its patent rights and applications on a straight line basis over the expected useful technological or economic life of the patents, which is typically 17 years from the legal approval of the patent applications when there is probable future economic benefits associated with the patent. The Company has elected to expense all of their patent rights and application costs due to difficulties associated with having to prove the value of their future economic benefits. All patent applications are currently pending and the Company has no patents that have yet been approved. It is the Company’s policy that it performs reviews of the carrying value of its patent rights and applications on an annual basis. On March 4, 2015, we entered into a Patent License Agreement (“PLA”) with the University of Texas at El Paso (“UTEP”) regarding our joint research and development of CTLA-4 Blockade with Metronomic Chemotherapy for the Treatment of Breast Cancer. This is the first PLA with UTEP following our Collaborative Agreement with them dated May 9, 2012, and memorializes the joint ownership of the applicable patent and the financial and other terms related thereto. On June 19, 2015, we entered into Amendment No. 1 to this Agreement, pursuant to which we explicitly included Provisional Patent Application No. 62/161,116 entitled, “Anti-CTLA-4 Blockade” (the “Application”) under the definition of “Patent Rights” as set forth in the PLA. The Application was filed with the United States Patent and Trademarks Office on May 13, 2015; the underlying technology was invented by Robert Kirken and Georgialina Rodriguez, and is solely-owned by The Board of Regents of The University of Texas System.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
Note 6 - Fair Value of Financial Instruments	Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2017 and December 31, 2016, respectively: Fair Value Measurements at June 30, 2017 Level 1 Level 2 Level 3 Assets Cash $ 125,341 $ - $ - Total assets 125,341 - - Liabilities Notes payable, related parties - 30,000 - Derivative liabilities - - 6,253,880 Total liabilities - 30,000 6,253,880 $ 125,341 $ (30,000 ) $ (6,253,880 ) Fair Value Measurements at December 31, 2016 Level 1 Level 2 Level 3 Assets Cash $ 22,437 $ - $ - Total assets 22,437 - - Liabilities Convertible note payable, net of discounts - 153,024 - Notes payable, related parties 30,000 - Derivative liabilities - - 221,822 Total liabilities - 183,024 221,822 $ 22,437 $ (183,024 ) $ (221,822 ) The fair values of our related party debts are deemed to approximate book value, and are considered Level 2 inputs as defined by ASC Topic 820-10-35. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the six months ended June 30, 2017 or the year ended December 31, 2016.	Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of December 31, 2016 and 2015, respectively: Fair Value Measurements at December 31, 2016 Level 1 Level 2 Level 3 Assets Cash $ 22,437 $ - $ - Total assets 22,437 - - Liabilities Convertible note payable, net of discounts - 153,024 - Notes payable, related parties - 30,000 - Total liabilities - 183,024 - $ 22,437 $ (183,024 ) $ - Fair Value Measurements at December 31, 2015 Level 1 Level 2 Level 3 Assets Cash $ 35,414 $ - $ - Total assets 35,414 - - Liabilities Convertible note payable, net of discounts - 41,815 - Notes payable, related parties - 30,000 - Total liabilities - 71,815 - $ 35,414 $ (71,815 ) $ - The fair values of our related party debts are deemed to approximate book value, and are considered Level 2 inputs as defined by ASC Topic 820-10-35. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the years ended December 31, 2016 or the year ended December 31, 2015.

Joint Venture

Joint Venture	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Joint Venture
Note 7 - Joint Venture	On September 13, 2016, we entered into an operating agreement to form a pain management joint venture company with Advanced Technologies Solutions (ATS), a company based in San Diego, California and owned by Ronald T. LaBorde, a member of our Board of Directors. The joint venture company, Premier Biomedical Pain Management Solutions, LLC, a Nevada limited liability company (PBPMS), will develop and market natural and cannabis-based generalized, neuropathic, and localized pain relief treatment products. We own 50% of PBPMS and ATS owns the other 50%, with 89% of the profits allocated to us and the remaining 11% of profits allocated to ATS. As part of the agreement with ATS, Mr. LaBorde was appointed a member of our Board of Directors. PBPMS must enter into separate license agreements with us and ATS for the use of technology previously developed by both companies. Intellectual property developed jointly by the parties will be the property of PBPMS. However, ATS and Mr. LaBorde may develop inventions and intellectual property independently from PBPMS, and such inventions and intellectual property will be the sole property of ATS or Mr. LaBorde. Pursuant to the terms of the PBPMS operating agreement, we will tender 1,250,000 warrants, for the purchase of an equal number of shares of our common stock at a strike price of $0.05, pursuant to the license agreement between ATS and PBPMS. As of June 30, 2017, we had not yet executed the license agreement or issued these warrants, and on July 5, 2017, we informed ATS that we have opted to terminate the joint venture company agreement. Our initial capital contribution to PBPMS was $25,000. ATS will contribute (i) technical, labor, manufacturing information and know-how required to produce the initial product, an extended duration topical pain relief patch; (ii) $5,000 worth of primary ingredients; and (iii) $5,000 worth of other materials to produce the initial prototype pain relief patches. PBPMS is managed by a board of managers (PBPMS Board). Initially, the PBPMS Board consists of William A. Hartman, our President and Chief Executive Officer and member of our Board of Directors, Ronald T. LaBorde, the Founder of ATS and member of our Board of Directors, Dr. Patricio Reyes, our Chief Technology Officer and member of our Board of Directors, and John Borza, our Vice-President and member of our Board of Directors. Decisions of the PBPMS Board require unanimous approval. The PBPMS operating agreement is subject to other common terms and ownership transfer restrictions, including a right of first refusal; however, we anticipate signing a more detailed and complete operating agreement to better clarify the terms of the joint venture as summarized above. During the six months ending June 30, 2017, we recognized $2,058 of equity in losses from our investment in the joint venture, and our share of the joint venture’s losses have exceeded our investment.	On September 13, 2016, we entered into an operating agreement to form a pain management joint venture company with Advanced Technologies Solutions (ATS), a company based in San Diego, California and owned by Ronald T. LaBorde, a member of our Board of Directors. The joint venture company, Premier Biomedical Pain Management Solutions, LLC, a Nevada limited liability company (PBPMS), will develop and market natural and cannabis-based generalized, neuropathic, and localized pain relief treatment products. We own 50% of PBPMS and ATS owns the other 50%, with 89% of the profits allocated to us and the remaining 11% of profits allocated to ATS. As part of the agreement with ATS, Mr. LaBorde was appointed a member of our Board of Directors. PBPMS must enter into separate license agreements with us and ATS for the use of technology previously developed by both companies. Intellectual property developed jointly by the parties will be the property of PBPMS. However, ATS and Mr. LaBorde may develop inventions and intellectual property independently from PBPMS, and such inventions and intellectual property will be the sole property of ATS or Mr. LaBorde. Pursuant to the terms of the PBPMS operating agreement, we will tender 1,250,000 warrants, for the purchase of an equal number of shares of our common stock at a strike price of $0.05, pursuant to the license agreement between ATS and PBPMS. As of December 31, 2016, we had not yet issued these warrants or commenced the joint venture. Our initial capital contribution to PBPMS is $25,000, which has not yet been funded. ATS will contribute (i) technical, labor, manufacturing information and know-how required to produce the initial product, an extended duration topical pain relief patch; (ii) $5,000 worth of primary ingredients; and (iii) $5,000 worth of other materials to produce the initial prototype pain relief patches. PBPMS will be managed by a board of managers (PBPMS Board). Initially, the PBPMS Board will consist of William A. Hartman, our President and Chief Executive Officer and member of our Board of Directors, Ronald T. LaBorde, the Founder of ATS and member of our Board of Directors, Dr. Patricio Reyes, our Chief Technology Officer and member of our Board of Directors, and John Borza, our Vice-President and member of our Board of Directors. Decisions of the PBPMS Board require unanimous approval. The PBPMS operating agreement is subject to other common terms and ownership transfer restrictions, including a right of first refusal; however, we anticipate signing a more detailed and complete operating agreement to better clarify the terms of the joint venture as summarized above. No activity, outside of the execution of this agreement, had commenced as of December 31, 2016.

Convertible Note Payable

Convertible Note Payable	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
Note 8 - Convertible Note Payable	Convertible notes payable consist of the following at June 30, 2017 and December 31, 2016, respectively: June 30, December 31, 2017 2016 On October 10, 2016, the Company issued a 10% interest bearing; unsecured convertible promissory note with a face value of $300,000 (“Seventh Redwood Note”), which matures on October 10, 2017, pursuant to a Warrant Purchase Agreement by and among Redwood Management, LLC, the Company and Typenex. Pursuant to this agreement, Redwood purchased the warrants from Typenex, and Typenex provided a Satisfaction of Judgment and Release of Garnishment to release the Writ of Garnishment Typenex had placed on our transfer agent. Redwood paid installment payments to Typenex in the aggregate amount of $300,000, which were completed on, or about November 10, 2016. The principal and interest of the Seventh Redwood Note is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. This settled the dispute with Typenex. A total of $308,750, consisting of $300,000 of principal and $8,750 of interest, was converted into 135,596,882 shares of common stock on various dates between November 21, 2016 and February 24, 2017. $ - $ 275,000 On March 11, 2016, the Company received net proceeds of $90,000 in exchange for a 10% interest bearing; unsecured convertible promissory note with a face value of $105,000 (“Fifth Redwood Note”), which matures on December 11, 2016. The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. A total of $120,517, consisting of $105,000 of principal and $15,517 of interest, was converted into an aggregate of 47,820,025 shares of common stock at various dates between November 8, 2016 and March 13, 2017. - 27,480 Total convertible notes payable - 302,480 Less unamortized derivative discounts: - 149,456 Convertible notes payable - 153,024 Less: current portion - 153,024 Convertible notes payable, less current portion $ - $ - The Company recognized interest expense for the six months ended June 30, 2017 and 2016, respectively, as follows: June 30, June 30, 2017 2016 Interest on convertible notes $ 2,691 $ 35,048 Interest on related party loans 1,200 1,200 Amortization of beneficial conversion feature - 81,648 Amortization of OID - 20,647 Amortization of loan origination costs - 44,811 Derivative discounts 149,456 225,457 Total interest expense $ 153,347 $ 408,811	Convertible notes payable consist of the following at December 31, 2016 and 2015, respectively: December 31, December 31, 2016 2015 On October 10, 2016, the Company issued a 10% interest bearing; unsecured convertible promissory note with a face value of $300,000 (“Seventh Redwood Note”), which matures on October 10, 2017, pursuant to a Warrant Purchase Agreement by and among Redwood Management, LLC, the Company and Typenex. Pursuant to this agreement, Redwood purchased the warrants from Typenex, and Typenex provided a Satisfaction of Judgment and Release of Garnishment to release the Writ of Garnishment Typenex had placed on our transfer agent. Redwood paid installment payments to Typenex in the aggregate amount of $300,000, which were completed on, or about November 10, 2016. The principal and interest of the Seventh Redwood Note is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. This settled the dispute with Typenex. A total of $25,000 of principal was converted into 8,620,690 shares of common stock on November 21, 2016. $ 275,000 $ - On May 27, 2016, the Company received net proceeds of $85,000 in exchange for a 10% interest bearing; unsecured convertible promissory note with a face value of $105,000 (“Sixth Redwood Note”), which matures on February 27, 2017. The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. A total of $106,879, consisting of $105,000 of principal and $1,879 of interest, was converted into an aggregate of 20,039,892 shares of common stock at various dates between July 13, 2016 and December 7, 2016. - - On March 11, 2016, the Company received net proceeds of $90,000 in exchange for a 10% interest bearing; unsecured convertible promissory note with a face value of $105,000 (“Fifth Redwood Note”), which matures on December 11, 2016. The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. A total of $81,070, consisting of $77,520 of principal and $3,550 of interest, was converted into an aggregate of 32,647,975 shares of common stock at various dates between November 8, 2016 and December 22, 2016. 27,480 - On March 7, 2016, the Company received net proceeds of $67,500 in exchange for a 10% interest bearing; unsecured convertible promissory note with a face value of $78,750 (“Fourth Redwood Note”), which matures on December 7, 2016. The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. A total of $83,930, consisting of $78,750 of principal and $5,180 of interest, was converted into an aggregate of 20,628,179 shares of common stock at various dates between October 26, 2016 and December 7, 2016. - - On February 24, 2016, the Company received net proceeds of $67,500 in exchange for a 10% interest bearing; unsecured convertible promissory note dated February 22, 2016 with a face value of $78,750 (“Third Redwood Note”), which matures on November 22, 2016. The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. A total of $83,357, consisting of $78,750 of principal and $4,607 of interest, was converted into an aggregate of 17,926,514 shares of common stock at various dates between August 26, 2016 and December 7, 2016. - - On January 8, 2016, the Company received net proceeds of $107,500 in exchange for a 10% interest bearing; unsecured convertible promissory note with a face value of $131,250 (“Second Redwood Note”), which matures on October 8, 2016. The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. A total of $131,250 of principal was converted into an aggregate of 23,360,868 shares of common stock at various dates between July 11, 2016 and August 1, 2016. - - On December 28, 2015, the Company received net proceeds of $130,000 in exchange for a 10% interest bearing; unsecured convertible promissory note dated December 28, 2015 with a face value of $157,500 (“First Redwood Note”), which matures on September 28, 2016. The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. A total of $164,007, consisting of $157,500 of principal and $6,507 of interest, was converted into an aggregate of 29,612,923 shares of common stock at various dates between April 6, 2016 and December 7, 2016. - 157,500 On December 15, 2015, the Company received net proceeds of $25,000 in exchange for a non-interest bearing, unsecured convertible promissory note with a face value of $27,500 (“Second JMJ Note”), which matures on December 15, 2016, as part of a larger financing agreement that enables the Company to draw total proceeds of $250,000 at the discretion of the lender. The principal and interest was convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of sixty percent (60%) of the lowest trading price of the Company’s common stock over the twenty five (25) trading days prior to the conversion request date, or a fixed rate of $0.00005 per share, as amended within the original promissory note on September 8, 2015 (In the case that conversion shares are not deliverable by DWAC an additional 10% discount will apply; and if the shares are ineligible for deposit into the DTC system and only eligible for Xclearing deposit an additional 5% discount shall apply; in the case of both an additional cumulative 15% discount shall apply). The note carries a one-time twelve percent (12%) of principal interest charge in the event of default, and the debt holder is limited to owning 4.99% of the Company’s issued and outstanding shares. The promissory note carried a $2,500 Original Issue Discount that was being amortized over the life of the loan on the straight line method, which approximates the effective interest method. The Company reserved at least 24 million shares of common stock for potential conversions. The note was paid in full on March 4, 2016 out of the proceeds from the Redwood Notes. - 27,500 On September 21, 2015, the Company received net proceeds of $45,000 in exchange for an 8% interest bearing; unsecured convertible promissory note dated September 3, 2015 with a face value of $48,000 (“First Vis Vires Note”), which matures on June 8, 2016. The principal and interest was convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of fifty eight percent (58%) of the average of the three (3) lowest closing bid prices over the 10 days prior to conversion, or a fixed rate of $0.00001 per share. The note included various prepayment penalties ranging from 112% through 130%, and default provisions of 150% of the then outstanding principal and interest, and an interest rate of 22% thereafter. The debt holder was limited to owning 4.99% of the Company’s issued and outstanding shares. The Company must at all times reserve at least 20,250,000 shares of common stock for potential conversions. The note was paid in full on January 19, 2016 out of the proceeds from the Redwood Notes. - 48,000 On September 2, 2015, the Company received net proceeds of $50,000 in exchange for a non-interest bearing, unsecured convertible promissory note with a face value of $55,000 (“First JMJ Note”), which matures on September 1, 2016, as part of a larger financing agreement that enables the Company to draw total proceeds of $250,000 at the discretion of the lender. The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of sixty percent (60%) of the lowest trading price of the Company’s common stock over the twenty five (25) trading days prior to the conversion request date, or a fixed rate of $0.00005 per share, as amended within the original promissory note on September 8, 2015 (In the case that conversion shares are not deliverable by DWAC an additional 10% discount will apply; and if the shares are ineligible for deposit into the DTC system and only eligible for Xclearing deposit an additional 5% discount shall apply; in the case of both an additional cumulative 15% discount shall apply). The note carries a one-time twelve percent (12%) of principal interest charge in the event of default, and the debt holder is limited to owning 4.99% of the Company’s issued and outstanding shares. The promissory note carries a $5,000 Original Issue Discount that is being amortized over the life of the loan on the straight line method, which approximates the effective interest method. The Company reserved at least 24 million shares of common stock for potential conversions. A total of $62,222, consisting of $55,000 of principal and $7,222 of interest, was converted into an aggregate of 12,359,944 shares of common stock at various dates between March 2, 2016 and April 19, 2016. - 55,000 Total convertible notes payable 302,480 288,000 Less unamortized debt discounts: Derivative discounts 149,456 129,422 Discounts on beneficial conversion feature - 81,648 Original issue discounts - 13,164 Loan origination discounts - 21,951 Convertible notes payable 153,024 41,815 Less: current portion 153,024 41,815 Convertible notes payable, less current portion $ - $ - The Company recognized interest expense for the years ended December 31, 2016 and 2015, respectively, as follows: December 31, December 31, 2016 2015 Interest on judgment payable $ 13,141 $ - Interest on convertible notes 52,720 21,172 Interest on related party loans 2,400 1,170 Amortization of derivative discounts 551,149 578 Amortization of loan origination costs 79,451 10,272 Amortization of beneficial conversion feature 81,648 117,500 Amortization of OID 36,914 14,384 Amortization of warrants issued with convertible notes - 32,973 Total interest expense $ 817,423 $ 198,049 In accordance with ASC 470-20 Debt with Conversion and Other Options, the Company recorded total discounts of $652,433 and $346,798 for the variable conversion features of the convertible debts incurred during the years ended December 31, 2016 and 2015, respectively. The discounts, as recognized below, are being amortized to interest expense over the term of the debentures using the effective interest method. The Company recorded $749,162 and $175,707 of interest expense pursuant to the amortization of note discounts during the years ended December 31, 2016 and 2015, respectively. The Company recognized interest expense for the years ended December 31, 2016 and 2015, respectively, as follows: December 31, December 31, 2016 2015 Derivative discounts $ 571,183 $ 130,000 Beneficial conversion feature discounts - 167,011 Original issue discounts 23,750 21,037 Loan origination costs 57,500 28,750 Total debt discounts $ 652,433 $ 346,798 All of the convertible debentures carry default provisions that place a “maximum share amount” on the note holders. The maximum share amount that can be owned as a result of the conversions to common stock by the note holders is 4.99% of the Company’s issued and outstanding shares. In accordance with ASC 815-15, the Company determined that the variable conversion feature and shares to be issued on the Redwood Notes represented embedded derivative features, and these are shown as derivative liabilities on the balance sheet. The Company calculated the fair value of the compound embedded derivatives associated with the convertible debentures utilizing a lattice model.

Other Current Assets

Other Current Assets	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Note 8 - Other Current Assets	Other current assets included the following as of June 30, 2017 and December 31, 2016, respectively: June 30, December 31, 2017 2016 Deposit on inventory purchase $ 52,100 $ - Other receivable, related party 48,778 - Prepaid expenses 17,743 11,430 $ 141,521 $ 11,430

Notes Payable, Related Parties

Notes Payable, Related Parties	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
Note 9 - Notes Payable, Related Parties	Notes payable, related parties consist of the following at June 30, 2017 and December 31, 2016, respectively: June 30, December 31, 2017 2016 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s CEO. $ 10,000 $ 10,000 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s Chairman of the Board. 10,000 10,000 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from one of the Company’s Directors. 10,000 10,000 Total notes payable, related parties 30,000 30,000 Less: current portion 30,000 30,000 Notes payable, related parties, less current portion $ - $ - The Company recorded interest expense in the amount of $1,200 and $1,200 for the six months ended June 30, 2017 and 2016, respectively related to notes payable, related parties.	Notes payable, related parties consist of the following at December 31, 2016 and 2015, respectively: December 31, December 31, 2016 2015 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s CEO. $ 10,000 $ 10,000 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s Chairman of the Board. 10,000 10,000 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from one of the Company’s Directors. 10,000 10,000 Total notes payable, related parties 30,000 30,000 Less: current portion 30,000 30,000 Notes payable, related parties, less current portion $ - $ - The Company recorded interest expense in the amount of $2,400 and $1,170 for the years ended December 31, 2016 and 2015, respectively related to notes payable, related parties. Accrued interest of $3,570 was outstanding on these notes as of December 31, 2016.

Derivative Liabilities

Derivative Liabilities	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
Note 10 - Derivative Liabilities	As discussed in Note 8 under Convertible Notes Payable, the Company issued debts that consist of the issuance of convertible notes with variable conversion provisions. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock. The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is indeterminate. Due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit, the equity environment is tainted and all additional convertible debentures and warrants are included in the value of the derivative. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the variable conversion option and warrants and shares to be issued were recorded as derivative liabilities on the issuance date. The fair values of the Company’s derivative liabilities were estimated at the issuance date and are revalued at each subsequent reporting date, using a lattice model. The Company recognized current derivative liabilities of $6,253,880 and $221,822 at June 30, 2017 and December 31, 2016, respectively. The change in fair value of the derivative liabilities resulted in a loss of $6,261,101 and a gain of $87,892 for the six months ended June 30, 2017 and 2016, respectively, which has been reported within other expense in the statements of operations. The loss of $6,261,101 for the six months ended June 30, 2017 consisted of a loss of $7,103,444 due to the value attributable to the warrants, a gain of $849,564 in market value of the warrants and a net loss in market value of $7,221 on the convertible notes. The loss of $87,862 for the six months ended June 30, 2016 consisted of a loss of $12,232 due to the value in excess of the face value of the convertible notes and a net loss in market value of $75,630 on the convertible notes. The following is a summary of changes in the fair market value of the derivative liability during the six months ended June 30, 2017 and the year ended December 31, 2016, respectively: Derivative Liability Total Balance, December 31, 2015 $ 150,076 Increase in derivative value due to issuances of convertible promissory notes 583,415 Change in fair market value of derivative liabilities due to the mark to market adjustment 13,816 Debt conversions (525,485 ) Balance, December 31, 2016 $ 221,822 Increase in derivative value due to issuances of warrants 7,103,444 Change in fair market value of derivative liabilities due to the mark to market adjustment (842,343 ) Debt conversions (229,043 ) Balance, June 30, 2017 $ 6,253,880 Key inputs and assumptions used to value the convertible debentures and warrants issued during the six months ended June 30, 2017: · Stock price ranging from $0.0435 to $0.0050 during these periods would fluctuate with projected volatility. · The notes convert with variable conversion prices and fixed conversion prices (tainted notes). · An event of default would occur -0-% of the time, increasing 1% per month to a maximum of 20%. · The projected annual volatility curve for each valuation period was based on the historical annual volatility of the company in the range of 145% - 385%. · The Company would redeem the notes -0-% of the time, increasing 1% per month to a maximum of 5%. · All notes are assumed to be extended at maturity by 2 years – the time required to convert out this volume of stock. · The holders of the securities would automatically convert midway through to maturity on a monthly basis based on ownership and trading volume limitations. · A change of control and fundamental transaction would occur initially -0-% of the time and increase monthly by -0-% to a maximum of -0-%. · The monthly trading volume would average $556,020 to $911,155 and would increase at 1% per month. · The stock price would fluctuate with the Company projected volatility using a random sampling (450,000 iterations for each valuation) from a normal distribution. The stock price of the underlying instrument is modelled such that it follows a geometric Brownian motion with constant drift and volatility. · The Holder would exercise the warrants after 1 trading day as they become exercisable (at issuance) at target prices of 3 times the projected reset price or higher. · Reset events were projected to occur by 12/31/17 and 12/31/18 – the reset provision ends 3/30/19 and the option expires 3/30/20. · The stock price would fluctuate with an annual volatility. The projected annual volatility curve for each valuation period was based on the historical annual volatility of the company and the term remaining in the range 261.86% - 261.99%. · The Holder would exercise the warrant at maturity 3/30/20 if the stock price was above the reset exercise price.	As discussed in Note 8 under Convertible Notes Payable, the Company issued debts that consist of the issuance of convertible notes with variable conversion provisions. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock. The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is indeterminate. Due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit, the equity environment is tainted and all additional convertible debentures and warrants are included in the value of the derivative. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the variable conversion option and warrants and shares to be issued were recorded as derivative liabilities on the issuance date. The fair values of the Company’s derivative liabilities were estimated at the issuance date and are revalued at each subsequent reporting date, using a lattice model. The Company recognized current derivative liabilities of $221,822 and $150,076 at December 31, 2016 and 2015, respectively. The change in fair value of the derivative liabilities resulted in a loss of $26,048 and a loss of $20,076 for the years ended December 31, 2016 and 2015, respectively, which has been reported within other expense in the statements of operations. The loss of $26,048 for the year ended December 31, 2016 consisted of a loss of $12,232 due to the value in excess of the face value of the convertible notes and a net loss in market value of 13,816 on the convertible notes. The loss of $20,076 for the year ended December 31, 2015 consisted of a loss of $14,748 due to the value in excess of the face value of the convertible notes and a net loss in market value of $5,328 on the convertible notes. The following is a summary of changes in the fair market value of the derivative liability during the years ended December 31, 2016 and 2015, respectively: Derivative Liability Total Balance, December 31, 2014 $ - Increase in derivative value due to issuances of convertible promissory notes 144,748 Change in fair market value of derivative liabilities due to the mark to market adjustment 5,328 Debt conversions - Balance, December 31, 2015 $ 150,076 Increase in derivative value due to issuances of convertible promissory notes 583,415 Change in fair market value of derivative liabilities due to the mark to market adjustment 13,816 Debt conversions (525,485 ) Balance, December 31, 2016 $ 221,822 Key inputs and assumptions used to value the convertible debentures and warrants issued during the years ended December 31, 2016 and 2015: · Stock price ranging from $0.0435 to $0.0050 during these periods would fluctuate with projected volatility. · The notes convert with variable conversion prices and fixed conversion prices (tainted notes). · An event of default would occur -0-% of the time, increasing 1% per month to a maximum of 20%. · The projected annual volatility curve for each valuation period was based on the historical annual volatility of the company in the range of 145% - 385%. · The Company would redeem the notes -0-% of the time, increasing 1% per month to a maximum of 5%. · All notes are assumed to be extended at maturity by 2 years – the time required to convert out this volume of stock. · The holders of the securities would automatically convert midway through to maturity on a monthly basis based on ownership and trading volume limitations. · A change of control and fundamental transaction would occur initially -0-% of the time and increase monthly by -0-% to a maximum of -0-%. · The monthly trading volume would average $556,020 to $911,155 and would increase at 1% per month.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
Note 11 - Commitments and Contingencies	Collaborative Patent License Agreements On May 9, 2012, the Company entered into a Collaborative Agreement with the University of Texas at El Paso. Pursuant to the terms of the Agreement, the Company will work jointly with the University to develop a series of research and development programs around its sequential-dialysis technology in the areas of Alzheimer's Disease, Traumatic Brain Injury (TBI), Chronic Pain Syndrome, Fibromyalgia, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease), Blood Sepsis, Cancer, Heart Attacks and Strokes. The programs will utilize the facilities at one or more of the University of Texas’ campuses. The Company will pay the University’s actual overhead for the projects, plus a negotiated facility and administration overhead expense, and 10% of all gross revenues associated with the sale, license and/or royalties of all products and treatment procedures directly affiliated with programs. Intellectual property jointly invented and developed as a result of the projects will be owned jointly by the University and the Company. The Agreement has an initial term of five (5) years, and is renewable upon mutual agreement of the parties. On March 4, 2015, we entered into a Patent License Agreement (PLA) with the University of Texas at El Paso (UTEP) regarding our joint research and development of CTLA-4 Blockade with Metronomic Chemotherapy for the Treatment of Breast Cancer. This is the first PLA with UTEP following our Collaborative Agreement with them dated May 9, 2012, and memorializes the joint ownership of the applicable patent and the financial and other terms related thereto. On June 19, 2015, we entered into Amendment No. 1 to this Agreement, pursuant to which we explicitly included Provisional Patent Application No. 62/161,116 entitled, “Anti-CTLA-4 Blockade” (the “Application”) under the definition of “Patent Rights” as set forth in the PLA. The Application was filed with the United States Patent and Trademarks Office on May 13, 2015; the underlying technology was invented by Robert Kirken and Georgialina Rodriguez, and is solely-owned by The Board of Regents of The University of Texas System.	Collaborative Patent License Agreements On May 9, 2012, the Company entered into a Collaborative Agreement with the University of Texas at El Paso. Pursuant to the terms of the Agreement, the Company will work jointly with the University to develop a series of research and development programs around its sequential-dialysis technology in the areas of Alzheimer's Disease, Traumatic Brain Injury (TBI), Chronic Pain Syndrome, Fibromyalgia, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease), Blood Sepsis, Cancer, Heart Attacks and Strokes. The programs will utilize the facilities at one or more of the University of Texas’ campuses. The Company will pay the University’s actual overhead for the projects, plus a negotiated facility and administration overhead expense, and 10% of all gross revenues associated with the sale, license and/or royalties of all products and treatment procedures directly affiliated with programs. Intellectual property jointly invented and developed as a result of the projects will be owned jointly by the University and the Company. The Agreement has an initial term of five (5) years, and is renewable upon mutual agreement of the parties. On March 4, 2015, we entered into a Patent License Agreement (PLA) with the University of Texas at El Paso (UTEP) regarding our joint research and development of CTLA-4 Blockade with Metronomic Chemotherapy for the Treatment of Breast Cancer. This is the first PLA with UTEP following our Collaborative Agreement with them dated May 9, 2012, and memorializes the joint ownership of the applicable patent and the financial and other terms related thereto. On June 19, 2015, we entered into Amendment No. 1 to this Agreement, pursuant to which we explicitly included Provisional Patent Application No. 62/161,116 entitled, “Anti-CTLA-4 Blockade” (the “Application”) under the definition of “Patent Rights” as set forth in the PLA. The Application was filed with the United States Patent and Trademarks Office on May 13, 2015; the underlying technology was invented by Robert Kirken and Georgialina Rodriguez, and is solely-owned by The Board of Regents of The University of Texas System. Common Stock Commitments On May 27, 2016, we entered into a Stock Purchase Agreement with Redwood Management, LLC, pursuant to which we agreed to sell, and Redwood, or its assigns, agreed to purchase, up to Two Million Dollars ($2,000,000) of our common stock. Pursuant to the terms of the Purchase Agreement, we may issue a purchase notice directing Redwood to purchase our common stock at a 20% discount to the lowest sale price of our common stock during the five (5) previous business days and in an amount of the lesser of (i) $150,000 or (ii) 100% of the average daily trading volume of our common stock in the ten (10) business days immediately preceding the date we give notice to Redwood. We may issue multiple purchase notices to Redwood, subject to these limitations, but we may not issue such a purchase notice to Redwood within ten (10) business days of the completion of funding under the prior purchase notice. We must have a registration statement in effect under the Securities Act that covers the resale of any shares of common stock sold to Redwood pursuant to the Purchase Agreement. We issued five purchase notices and received aggregate proceeds of $143,520 pursuant to the issuance of 27,952,890 shares of common stock over various dates between July 21, 2016 and December 13, 2016. Typenex Judgment On July 28, 2016, the Third Judicial District Court of Salt Lake County in the State of Utah awarded Typenex Co-Investment, LLC a Default Judgment in the amount of $340,647, pursuant to a dispute over the number of warrants that Typenex was awarded with their convertible note entered into on November 25, 2014. The outstanding judgment award carries an interest rate of 22% until the judgment amount is paid in full. The Company had accrued the potential liability, and on October 10, 2016, we entered into a Warrant Purchase Agreement by and among Redwood Management, LLC, the Company and Typenex. Pursuant to this agreement, Redwood purchased the warrants from Typenex, and Typenex provided a Satisfaction of Judgment and Release of Garnishment to release the Writ of Garnishment Typenex had placed on our transfer agent. Redwood paid installment payments to Typenex in the aggregate amount of $300,000 through November of 2016 to settle the judgment. In conjunction with this transaction, we entered into an Exchange Agreement with Redwood whereby, in exchange for the warrants that Redwood purchased from Typenex, we issued a 10% Convertible Promissory Note to Redwood with a principal amount of $300,000. This settled the dispute with Typenex upon satisfaction of the payments to Typenex over various dates in October and November of 2016, and the warrants were cancelled. A total of $13,141 of interest had been accrued, which together with the $340,647 default judgment, resulted in a gain on extinguishment of $53,788.

Stockholders Equity

Stockholders Equity	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
Note 12 - Stockholders Equity	Convertible Preferred Stock, Series A The Company has 10,000,000 authorized shares of Preferred Stock, of which 2,000,000 shares of $0.001 par value Series A Convertible Preferred Stock (“Series A Preferred Stock”) have been designated. Each share of Series A Preferred Stock is convertible, at the option of the holder thereof, at any time after the issuance of such share into one (1) fully paid and non-assessable share of Common Stock. Each outstanding share of Series A Preferred Stock is entitled to one hundred (100) votes per share on all matters to which the shareholders of the Corporation are entitled or required to vote. The Company shall reserve and keep available out of its authorized but unissued shares of Common Stock such number of shares sufficient to effect the conversions. Common Stock The Company has one billion authorized shares of $0.00001 par value Common Stock, as increased pursuant to an amendment to the articles of incorporation on February 9, 2016. Securities Purchase Agreement On March 30, 2017, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) by and between the Company and each of The Special Equities Group, LLC, RDW Capital LLC, and DiamondRock, LLC (each a “Purchaser” and collectively, the “Purchasers”) to sell our common stock and warrants at a fixed price. Pursuant to the Purchase Agreement, we received from the Purchasers an aggregate of $300,000, net of $15,000 of offering costs, in exchange for 40,000,002 shares of our common stock, warrants to purchase up to 40,000,002 shares of our common stock at an exercise price of $0.03 (“Series A Warrants”) and warrants to purchase up to 40,000,002 shares or our common stock at an exercise price of $0.05 (“Series B Warrants”). Both the Series A Warrants and Series B Warrants issued pursuant to the Purchase Agreement are exercisable immediately upon receipt and have a term of three years. In addition, the Purchaser is entitled to a one-time price reset on the purchase price of the common stock of each tranche to the lower of (i) $0.02 or (ii) a 50% discount to the average of the three lowest closing prices in the 20 trading days prior to the reset date, which is the earlier of (i) the 7 month anniversary of the closing of each tranche of this transaction or (ii) 20 trading days after the effectiveness of each tranche. The embedded value in this reset provision is disclosed further in Note 10. On May 30, 2017, the Purchasers bought additional shares of our common stock and warrants for $150,000 (the “Second Closing”), in exchange for 30,303,033 shares of our common stock, warrants to purchase up to 30,303,033 shares of our common stock at an exercise price of $0.03 (“Series A Warrants”) and warrants to purchase up to 30,303,033 shares or our common stock at an exercise price of $0.05 (“Series B Warrants”). Both the Series A Warrants and Series B Warrants issued pursuant to the Purchase Agreement are exercisable immediately upon receipt and have a term of three years. The per share purchase price of the Second Closing was the lesser of (i) $0.02, subject to certain adjustments for stock splits and other similar transactions, or (ii) 50% of the closing price on the trading day immediately prior to the date of sale. The total number of shares to be sold in the Second Closing were determined by dividing the total purchase amount of each closing (i.e., $150,000) by the per share purchase price. The Purchase Agreement limits each Purchaser to beneficial ownership of our common stock of no more than 9.99%. The Purchasers also have certain anti-dilution rights in the Purchase Agreement for a period of 12 months. These rights allow the Purchasers to exchange their shares of common stock received pursuant to the Purchase Agreement for additional shares on the same terms and conditions of a subsequent financing. On August 8, 2017, the Company and each of the three Purchasers also entered into exchange agreements whereby the Purchasers exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (aggregate $150,000) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Registration Rights Agreement On March 30, 2017, we entered into a Registration Rights Agreement with the Purchasers in connection with the Purchase Agreement. In the Registration Rights Agreement, we agreed to prepare and file a registration statement with the Securities and Exchange Commission covering the resale of all of the shares of common stock sold to the Purchasers and the shares issuable upon exercise of the Series A Warrants and Series B Warrants. We agreed to file an initial registration statement as promptly as possible and have it declared effective no later than June 28, 2017 (or July 28, 2017 if the registration statement was reviewed by the Securities and Exchange Commission) and keep it continuously effective until the securities are sold or may be sold under Rule 144 of the Securities Act without volume or manner-of-sale restrictions. If all of the securities cannot be registered on one registration statement, we agreed to file subsequent registration statements to register the remaining securities as promptly as allowed. The registration statement was subsequently withdrawn on July 24, 2017 and the Purchase Agreement was amended on August 8, 2017 to change the terms of the third closing to an aggregate of $150,000 of convertible notes, bearing interest at 8%, convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Common Stock Issuances for Debt Conversions On various dates between January 10, 2017 and March 13, 2017, the Company issued a total of 142,148,242 shares of common stock pursuant to the conversion of an aggregate of $323,197, consisting of $302,480 of principal and $20,717 of interest, among the Second, Fifth and Seventh Redwood Notes. The notes were converted in accordance with the conversion terms; therefore no gain or loss has been recognized. Common Stock Issuances on Stock Purchase Agreement On February 13, 2017, the Company drew down $8,000 on their Stock Purchase Agreement entered into on May 27, 2016, with Redwood and issued 2,000,000 shares of common stock pursuant to the Seventh Put Notice. On January 10, 2017, the Company drew down $10,323 on their Stock Purchase Agreement entered into on May 27, 2016, with Redwood and issued 3,147,110 shares of common stock pursuant to the Sixth Put Notice.	Convertible Preferred Stock, Series A The Company has 10,000,000 authorized shares of Preferred Stock, of which 2,000,000 shares of $0.001 par value Series A Convertible Preferred Stock (“Series A Preferred Stock”) have been designated. Each share of Series A Preferred Stock is convertible, at the option of the holder thereof, at any time after the issuance of such share into one (1) fully paid and non-assessable share of Common Stock. Each outstanding share of Series A Preferred Stock is entitled to one hundred (100) votes per share on all matters to which the shareholders of the Corporation are entitled or required to vote. The Company shall reserve and keep available out of its authorized but unissued shares of Common Stock such number of shares sufficient to effect the conversions. Preferred Stock Issuances for Exercise of Preferred Stock Warrants, Related Parties On January 29, 2016, the Company issued 1,000,000 shares of series A preferred stock pursuant to the exercise of warrants by the Company’s CEO at $0.001 per share for total proceeds of $1,000. On January 29, 2016, the Company issued 1,000,000 shares of series A preferred stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.001 per share for total proceeds of $1,000. Common Stock The Company has one billion authorized shares of $0.00001 par value Common Stock, as increased pursuant to an amendment to the articles of incorporation on February 9, 2016. Common Stock Issuances for Debt Conversions (2016) On various dates between April 6, 2016 and December 22, 2016, the Company issued a total of 152,837,041 shares of common stock pursuant to the conversion of an aggregate of $675,494, consisting of $653,771 of principal and $21,723 of interest, among the Seven Redwood Notes. The notes were converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On April 19, 2016, the Company issued 3,159,944 shares of common stock pursuant to the conversion of $10,238 of principal on the First JMJ Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On April 11, 2016, the Company issued 2,800,000 shares of common stock pursuant to the conversion of $9,744 of principal on the First JMJ Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On March 17, 2016, the Company issued 4,400,000 shares of common stock pursuant to the conversion of $29,040 of principal on the First JMJ Financial Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On March 2, 2016, the Company issued 2,000,000 shares of common stock pursuant to the conversion of $13,200 of principal on the First JMJ Financial Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. Common Stock Issuances on Stock Purchase Agreement (2016) On December 13, 2016, the Company drew down $25,000 on their Stock Purchase Agreement entered into on May 27, 2016, with Redwood and issued 6,250,000 shares of common stock pursuant to the Fifth Put Notice. On November 22, 2016, the Company drew down $25,000 on their Stock Purchase Agreement entered into on May 27, 2016, with Redwood and issued 6,377,551 shares of common stock pursuant to the Fourth Put Notice. On November 8, 2016, the Company drew down $25,000 on their Stock Purchase Agreement entered into on May 27, 2016, with Redwood and issued 6,097,561 shares of common stock pursuant to the Third Put Notice. On August 12, 2016, the Company drew down $39,520 on their Stock Purchase Agreement entered into on May 27, 2016, with Redwood and issued 5,200,000 shares of common stock pursuant to the Second Put Notice. On July 21, 2016, the Company drew down $29,000 on their Stock Purchase Agreement entered into on May 27, 2016, with Redwood and issued 4,027,778 shares of common stock pursuant to the First Put Notice. Common Stock Issuances for Exercise of Common Stock Warrants (2016) On December 23, 2016, the Company issued 6,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s CEO at $0.00001 per share for total proceeds of $60. On December 23, 2016, the Company issued 6,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.00001 per share for total proceeds of $60. On October 19, 2016, the Company issued 4,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s CEO at $0.00001 per share for total proceeds of $40. On October 19, 2016, the Company issued 4,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.00001 per share for total proceeds of $40. On February 10, 2016, the Company issued 2,248,846 shares of common stock pursuant to the cashless exercise of 2,250,000 warrants by the Company’s securities attorney at $0.00001 per share. Common Stock Issuances for Debt Financing (2016) On February 10, 2016, the Company issued 600,000 shares of our common stock to a third-party for services rendered in connection with our recent financing transactions with Redwood Fund III, Ltd. The total fair value of the common stock was $9,600 based on the closing price of the Company’s common stock on the date of grant. On February 10, 2016, the Company issued 2,400,000 shares of our common stock to a third-party for services rendered in connection with our recent financing transactions with Redwood Fund III, Ltd. The total fair value of the common stock was $38,400 based on the closing price of the Company’s common stock on the date of grant. Common Stock Issuances for Settlement of Accounts Payments, Related Party (2016) On March 28, 2016, upon the resignation of Richard Najarian as one of the members of our Board of Directors, the Company issued 600,000 shares of common stock to Mr. Najarian in settlement of $13,765 of outstanding expense reimbursements. The total fair value of the common stock was $9,120 based on the closing price of the Company’s common stock on the date of grant. Common Stock Issuances for Services (2016) On November 14, 2016, we issued 2,626,867 shares of our common stock to a third-party for legal services rendered. The total fair value of the common stock was $11,821 based on the closing price of the Company’s common stock on the date of grant. On February 12, 2016, we issued 600,000 shares of our common stock to a third-party for services rendered in connection with our recent financing transactions. The total fair value of the common stock was $10,800 based on the closing price of the Company’s common stock on the date of grant. Common Stock Issuances for Debt Conversions (2015) On December 15, 2015, the Company issued 1,762,516 shares of common stock pursuant to the conversion of $16,039, consisting of $15,000 of principal and $1,039 of interest, on the First LG Capital Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On December 8, 2015, the Company issued 2,794,392 shares of common stock pursuant to the conversion of $18,094, consisting of $16,946 of principal and $1,148 of interest, on the First LG Capital Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On December 4, 2015, the Company issued 1,526,070 shares of common stock pursuant to the conversion of $3,258, consisting of $3,054 of principal and $204 of interest, on the First LG Capital Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On December 2, 2015, the Company issued 3,022,017 shares of common stock pursuant to the conversion of $5,183, consisting of $4,860 of principal and $323 of interest, on the First LG Capital Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On December 1, 2015, the Company issued 4,441,702 shares of common stock pursuant to the conversion of $7,413, consisting of $559 of principal and $6,854 of interest, on the First Typenex Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On November 25, 2015, the Company issued 3,003,665 shares of common stock pursuant to the conversion of $4,941, consisting of $4,640 of principal and $301 of interest, on the First LG Capital Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On November 17, 2015, the Company issued 2,261,963 shares of common stock pursuant to the conversion of $3,721, consisting of $3,500 of principal and $221 of interest, on the First LG Capital Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On November 16, 2015, the Company issued 3,000,000 shares of common stock pursuant to the conversion of $5,007 of principal on the First Typenex Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On November 12, 2015, the Company issued 2,400,940 shares of common stock pursuant to the conversion of $4,370, consisting of $2,115 of principal and $2,255 of interest, on the First Adar Bay Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On November 11, 2015, the Company issued 2,259,167 shares of common stock pursuant to the conversion of $3,716, consisting of $3,500 of principal and $216 of interest, on the First LG Capital Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On November 11, 2015, the Company issued 2,375,275 shares of common stock pursuant to the conversion of $4,323 of principal on the First Adar Bay Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On November 9, 2015, the Company issued 2,375,000 shares of common stock pursuant to the conversion of $4,322 of principal on the First Adar Bay Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On November 9, 2015, the Company issued 3,510,000 shares of common stock pursuant to the conversion of $6,234 of principal on the First Typenex Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On November 6, 2015, the Company issued 1,979,568 shares of common stock pursuant to the conversion of $3,256, consisting of $3,070 of principal and $186 of interest, on the First LG Capital Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On November 2, 2015, the Company issued 2,168,067 shares of common stock pursuant to the conversion of $5,160 of principal on the First Adar Bay Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On October 27, 2015, the Company issued 1,839,530 shares of common stock pursuant to the conversion of $4,700 of principal on the First Adar Bay Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On October 26, 2015, the Company issued 1,620,522 shares of common stock pursuant to the conversion of $3,630, consisting of $3,430 of principal and $200 of interest, on the First LG Capital Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On October 26, 2015, the Company issued 1,753,425 shares of common stock pursuant to the conversion of $4,480 of principal on the First Adar Bay Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On October 26, 2015, the Company issued 3,091,128 shares of common stock pursuant to the conversion of $7,700 of principal on the First Typenex Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On October 19, 2015, the Company issued 1,284,109 shares of common stock pursuant to the conversion of $6,000 of principal on the First Adar Bay Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On October 13, 2015, the Company issued 1,076,992 shares of common stock pursuant to the conversion of $4,222, consisting of $4,000 of principal and $222 of interest, on the First LG Capital Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On October 8, 2015, the Company issued 1,116,799 shares of common stock pursuant to the conversion of $6,000 of principal on the First Adar Bay Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On October 1, 2015, the Company issued 2,344,032 shares of common stock pursuant to the conversion of $13,000 of principal on the First Typenex Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On September 18, 2015, the Company issued 681,800 shares of common stock pursuant to the conversion of $6,300, consisting of $6,000 of principal and $300 of interest on the First LG Capital Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On September 3, 2015, the Company issued 459,242 shares of common stock pursuant to the conversion of $7,000 of principal on the First Adar Bay Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On August 26, 2015, the Company issued 446,711 shares of common stock pursuant to the conversion of $6,270, consisting of $6,000 of principal and $270 of interest on the First LG Capital Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On August 25, 2015, the Company issued 823,121 shares of common stock pursuant to the conversion of $13,500 of principal on the First Typenex Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On August 17, 2015, the Company issued 371,556 shares of common stock pursuant to the conversion of $5,215, consisting of $5,000 of principal and $215 of interest on the First LG Capital Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On August 4, 2015, the Company issued 292,181 shares of common stock pursuant to the conversion of $3,835, consisting of $3,687 of principal and $148 of interest, on the First LG Capital Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On July 23, 2015, the Company issued 260,866 shares of common stock pursuant to the conversion of $13,000 of principal on the First Typenex Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On June 25, 2015, the Company issued 208,719 shares of common stock pursuant to the conversion of $15,000 of principal on the First Typenex Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On June 3, 2015, the Company issued 172,812 shares of common stock pursuant to the conversion of $12,500 of principal on the First Typenex Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. Common Stock Issuances for Exercise of Warrants, Related Party (2015) On October 1, 2015, the Company issued 3,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.00001 per share for total proceeds of $30. On September 10, 2015, the Company issued 1,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.00001 per share for total proceeds of $10. Common Stock Cancellations (2015) On August 12, 2015, the Company cancelled and returned to treasury a total of 150,000 shares of common stock previously issued to a consultant for services provided. Beneficial Conversion Feature On December 24, 2015, the Company entered into a convertible promissory note with JMJ Financial. The beneficial conversion feature discount resulting from the conversion price that was $0.03262 below the market price of $0.034 on the origination date of December 24, 2015, resulted in a debt discount value of $25,000 that was recognized as additional paid in capital and was amortized on a straight line basis over the life of the loan. On September 21, 2015, the Company entered into a convertible promissory note with Vis Vires Group, Inc. The beneficial conversion feature discount resulting from the conversion price that was $0.00747 below the market price of $0.016 on the origination date of September 21, 2015, resulted in a debt discount value of $39,448 that was recognized as additional paid in capital and was amortized on a straight line basis over the life of the loan. On September 2, 2015, the Company entered into a convertible promissory note with JMJ Financial. The beneficial conversion feature discount resulting from the conversion price that was $0.0194 below the market price of $0.032 on the origination date of September 2, 2015, resulted in a debt discount value of $50,000 that was recognized as additional paid in capital and was amortized on a straight line basis over the life of the loan. On February 24, 2015, the Company entered into a convertible promissory note with Adar Bays, LLC. The beneficial conversion feature discount resulting from the conversion price that was $0.0473 below the market price of $0.14 on the origination date of February 24, 2015, resulted in a debt discount value of $20,420 that was recognized as additional paid in capital and was amortized on a straight line basis over the life of the loan. On January 30, 2015, the Company entered into a convertible promissory note with LG Capital Funding, LLC. The beneficial conversion feature discount resulting from the conversion price that was $0.042 below the market price of $0.14 on the origination date of January 30, 2015, resulted in a debt discount value of $32,143 that was recognized as additional paid in capital and was amortized on a straight line basis over the life of the loan.

Series A Convertible Preferred

Series A Convertible Preferred Stock Warrants	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Note 13 - Series A Convertible Preferred Stock Warrants	Series A Convertible Preferred Stock Warrants Granted No series A preferred stock warrants were granted during the years ended December 31, 2016 and 2015. Series A Preferred Stock Warrants Cancelled No series A preferred stock warrants were cancelled during the years ended December 31, 2016 and 2015. Series A Preferred Stock Warrants Expired No series A preferred stock warrants were expired during the years ended December 31, 2016 and 2015. Series A Preferred Stock Warrants Exercised On January 29, 2016, the Company issued 1,000,000 shares of series A preferred stock pursuant to the exercise of warrants by the Company’s CEO at $0.001 per share for total proceeds of $1,000. On January 29, 2016, the Company issued 1,000,000 shares of series A preferred stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.001 per share for total proceeds of $1,000. No series A preferred stock warrants were exercised during the year ended December 31, 2015. No Series A Preferred Stock Warrants were outstanding at December 31, 2016. The following is a summary of activity of outstanding series A preferred stock warrants: Weighted Average Number of Exercise Shares Price Balance, December 31, 2014 2,000,000 $ 0.001 Warrants expired - - Warrants granted - - Warrants exercised - - Balance, December 31, 2015 2,000,000 $ 0.001 Warrants expired - - Warrants granted - - Warrants exercised (2,000,000 ) (0.001 ) Balance, December 31, 2016 - $ - Exercisable, December 31, 2016 - $ -

Common Stock Warrants

Common Stock Warrants	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Note 14 - Common Stock Warrants	Common Stock Warrants Granted (2015) On October 7, 2015, the Company granted warrants to the following officers and directors, which will allow them to purchase shares of our common stock in the amounts indicated: William Hartman (1,000,000 shares); Mitchell Felder (1,000,000 shares), Heidi Carl (750,000 shares), John Borza (600,000 shares), Richard Najarian (200,000 shares), and Jay Rosen (200,000 shares). The exercise price of the foregoing warrants is five cents ($0.05) per share. The warrants are exercisable over ten (10) years. The total fair value of the 3,750,000 common stock warrants using the Black-Scholes option-pricing model is $31,109, or $0.0083 per share, based on a volatility rate of 232%, a risk-free interest rate of 1.75% and an expected term of 10 years, and is being amortized over the implied service term, or vesting period, of the warrants. One half of the shares underlying each of the respective warrants vest on June 15, 2016, with the balance vesting on December 15, 2016. In order for the warrants to vest on each of the foregoing dates, however, the holders must be serving in the same capacity on behalf of the Company as he or she was serving on October 21, 2015. The issuance of the warrants was fully approved by our Board of Directors on October 21, 2015, the date a fully executed resolution authorizing the issuance was delivered. The Company recognized a total of $25,030 and $6,079 of professional fee expense during the years ended December 31, 2016 and 2015, respectively. On October 7, 2015, we also issued warrants to purchase a total of one million eight hundred thousand (1,800,000) shares of our common stock amongst six members of our Scientific Advisory Board. The exercise price of the foregoing warrants is five cents ($0.05) per share. The warrants are exercisable over ten (10) years. The total fair value of the 1,800,000 common stock warrants using the Black-Scholes option-pricing model is $14,931, or $0.0083 per share, based on a volatility rate of 232%, a risk-free interest rate of 1.75% and an expected term of 10 years. In accordance with Accounting Standards Codification (“ASC”) 505-50, non-employee stock based compensation awards are re-measured at each period. One half of the shares underlying each of the respective warrants vest on June 15, 2016, with the balance vesting on December 15, 2016. In order for the warrants to vest on each of the foregoing dates, however, the holders must be serving in the same capacity on behalf of the Company as he or she was serving on October 21, 2015. The issuance of the warrants was fully approved by our Board of Directors on October 21, 2015, the date a fully executed resolution authorizing the issuance was delivered. The Company recognized a total of $14,739 and $14,421 of professional fee expense during the years ended December 31, 2016 and 2015, respectively. On July 25, 2015, the Company granted cashless common stock warrants to an independent contractor to purchase a total of 500,000 shares of common stock at $0.10 per share for advisory services. The warrants are exercisable over seven (7) years from July 25, 2015. The warrants vest in full on December 1, 2015. The initial estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 204% and a call option value of $0.0497, was $24,872. In accordance with Accounting Standards Codification (“ASC”) 505-50, non-employee stock based compensation awards are re-measured at each period. The total fair value of the 500,000 common stock warrants using the Black-Scholes option-pricing model was re-measured at $4,720, or $0.0094 per share as of September 30, 2015, based on a volatility rate of 232%, a risk-free interest rate of 1.75% and an expected term of 7 years. The Company recognized a total of $-0- and $11,943 of professional fee expense during the years ended December 31, 2016 and 2015, respectively. On May 30, 2015, the Company granted cashless common stock warrants to an independent contractor to purchase a total of 500,000 shares of common stock at $0.25 per share for advisory services. The warrants are exercisable over seven (7) years from May 30, 2015. The warrants vest in full on December 1, 2015. The initial estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 199% and a call option value of $0.13751, was $68,756. In accordance with Accounting Standards Codification (“ASC”) 505-50, non-employee stock based compensation awards are re-measured at each period. The total fair value of the 500,000 common stock warrants using the Black-Scholes option-pricing model was re-measured at $4,706, or $0.0094 per share as of September 30, 2015, based on a volatility rate of 232%, a risk-free interest rate of 1.75% and an expected term of 7 years. The Company recognized a total of $-0- and $11,939 of professional fee expense during the years ended December 31, 2016 and 2015, respectively. On March 20, 2015, the Company granted cashless common stock warrants to an independent contractor to purchase a total of 500,000 shares of common stock at $0.20 per share for investor relation services. The warrants are exercisable over five (5) years from March 20, 2015. The warrants vest in accordance with the schedule presented below, whereby the price per share is defined by the closing bid price over three consecutive trading days: · 125,000 warrants will vest at $0.20 per share · 125,000 warrants will vest at $0.30 per share · 125,000 warrants will vest at $0.40 per share · 125,000 warrants will vest at $0.50 per share The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 204% and a call option value of $0.1166, was $58,301. The vesting period is indeterminate, therefore, the Company recognized the entire $58,301 of stock based compensation expense during the year ended December 31, 2015. A total of $39,769 and $1,849,169 of warrants were amortized and expensed to professional fees as stock-based compensation during the years ended December 31, 2016 and 2015, respectively, including $25,030 and $1,529,182 during the years ended December 31, 2016 and 2015, respectively, related to warrants issued to related parties. Common Stock Warrants Cancelled A total of 351,455 warrants exercisable at the lesser of (i) $0.18, and (ii) 70% of the Market Price, which is the average of the three (3) lowest VWAPs, not less than a fixed floor of $0.0001, during the twenty (20) trading day period ending on the last complete trading day prior to the date the conversion notice is delivered, or 65% if that price is less than $0.10 per share was cancelled during the year ended December 31, 2016 pursuant to the settlement reached with Typenex. No warrants were cancelled during the year ended December 31, 2015. Common Stock Warrants Expired A total of 300,000 and 50,000 warrants exercisable at $0.96 and $0.25 per share expired during years ended December 31, 2016 and 2015, respectively. Exercise of Common Stock Warrants (2016) On February 10, 2016, the Company issued 2,248,846 shares of common stock pursuant to the cashless exercise of 2,250,000 warrants by the Company’s securities attorney at $0.00001 per share. Exercise of Common Stock Warrants, Related Party (2016) On December 23, 2016, the Company issued 6,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s CEO at $0.00001 per share for total proceeds of $60. On December 23, 2016, the Company issued 6,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.00001 per share for total proceeds of $60. On October 19, 2016, the Company issued 4,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s CEO at $0.00001 per share for total proceeds of $40. On October 19, 2016, the Company issued 4,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.00001 per share for total proceeds of $40. Common Stock Issuances for Exercise of Warrants, Related Party (2015) On October 1, 2015, the Company issued 3,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.00001 per share for total proceeds of $30. On September 10, 2015, the Company issued 1,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.00001 per share for total proceeds of $10. The following is a summary of information about the Common Stock Warrants outstanding at December 31, 2016. Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $ 0.00001 – $1.45 30,690,000 4.91 years $ 0.24407 30,690,000 $ 0.24407 The fair value of each warrant grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: December 31, December 31, 2016 2015 Average risk-free interest rates N/A 1.75 % Average expected life (in years) N/A 9.22 The Black-Scholes option pricing model was developed for use in estimating the fair value of short-term traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including expected stock price volatility. Because the Company’s common stock warrants have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion the existing models do not necessarily provide a reliable single measure of the fair value of its common stock warrants. During the years ended December 31, 2016 and 2015 there were no warrants granted with an exercise price below the fair value of the underlying stock at the grant date. The weighted average fair value of warrants granted with exercise prices at the current fair value of the underlying stock was approximately $0.0784 per warrant granted during the year ended December 31, 2015. The following is a summary of activity of outstanding common stock warrants: Weighted Average Number of Exercise Shares Price Balance, December 31, 2014 50,591,455 $ 0.1443 Warrants expired (50,000 ) (0.25 ) Warrants granted 7,050,000 0.0784 Warrants exercised (4,000,000 ) (0.00001 ) Balance, December 31, 2015 53,591,455 $ 0.1463 Warrants cancelled (351,455 ) (0.18 ) Warrants expired (300,000 ) (0.96 ) Warrants exercised (22,250,000 ) (0.00001 ) Balance, December 31, 2016 30,690,000 $ 0.24407 Exercisable, December 31, 2016 30,690,000 $ 0.24407

Income Taxes

Income Taxes	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
Note 15 - Income Taxes	The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. For the six months ended June 30, 2017, and the year ended December 31, 2016, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At June 30, 2017, and December 31, 2016, the Company had approximately $4,656,000 and $4,334,000 of federal net operating losses, respectively. The net operating loss carry forwards, if not utilized, will begin to expire in 2031. The components of the Company’s deferred tax asset are as follows: June 30, December 31, 2017 2016 Deferred tax assets: Net operating loss carry forwards $ 1,629,600 $ 1,516,900 Net deferred tax assets before valuation allowance $ 1,629,600 $ 1,516,900 Less: Valuation allowance (1,629,600 ) (1,516,900 ) Net deferred tax assets $ - $ - Based on the available objective evidence, including the Company’s history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at June 30, 2017, and December 31, 2016, respectively. A reconciliation between the amounts of income tax benefit determined by applying the applicable U.S. and state statutory income tax rate to pre-tax loss is as follows: June 30, December 31, 2017 2016 Federal and state statutory rate 35 % 35 % Change in valuation allowance on deferred tax assets (35 %) (35%) In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.	The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. For the years ended December 31, 2016 and 2015, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At December 31, 2016 and December 31, 2015, the Company had approximately $4,334,000 and $2,663,000 of federal net operating losses, respectively. The net operating loss carry forwards, if not utilized, will begin to expire in 2031. The components of the Company’s deferred tax asset are as follows: December 31, December 31, 2016 2015 Deferred tax assets: Net operating loss carry forwards $ 1,516,900 $ 932,050 Net deferred tax assets before valuation allowance $ 1,516,900 $ 932,050 Less: Valuation allowance (1,516,900 ) (932,050 ) Net deferred tax assets $ - $ - Based on the available objective evidence, including the Company’s history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at December 31, 2016 and 2015, respectively. A reconciliation between the amounts of income tax benefit determined by applying the applicable U.S. and State statutory income tax rate to pre-tax loss is as follows: December 31, December 31, 2016 2015 Federal and state statutory rate 35 % 35 % Change in valuation allowance on deferred tax assets (35 %) (35 %) In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

Subsequent Events

Subsequent Events	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
Note 16 - Subsequent Events	Convertible Notes Exchanged for Previously Issued Shares of Common Stock and Warrants On August 8, 2017, the Company and each of the three Purchasers entered into exchange agreements whereby the Purchasers exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (aggregate $150,000) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Termination of Joint Ventue On July 5, 2017, we informed Advanced Technologies Solutions (ATS), owned by Ronald T. La Borde, a member of our Board of Directors, that we have opted to terminate the joint venture company agreement.	Securities Purchase Agreement On March 30, 2017, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) by and between the Company and each of The Special Equities Group, LLC, RDW Capital LLC, and DiamondRock, LLC (each a “Purchaser” and collectively, the “Purchasers”) to sell our common stock and warrants at a fixed price. Pursuant to the Purchase Agreement, we received from the Purchasers an aggregate of $300,000 in exchange for 40,000,002 shares of our common stock, warrants to purchase up to 40,000,002 shares of our common stock at an exercise price of $0.03 (“Series A Warrants”) and warrants to purchase up to 40,000,002 shares or our common stock at an exercise price of $0.05 (“Series B Warrants”). Both the Series A Warrants and Series B Warrants issued pursuant to the Purchase Agreement are exercisable immediately upon receipt and have a term of three years. The Purchasers will buy additional shares of our common stock and warrants for $150,000 within five trading days of our filing a registration statement to cover the Purchasers’ shares of common stock purchased pursuant to the Purchase Agreement, including shares of common stock issued or issuable upon exercise of the warrants (the “Second Closing”). Within five trading days of the registration statement being declared effective, we will receive another $150,000 from the Purchasers in exchange for shares or our common stock and warrants (the “Third Closing”). The per share purchase price of the Second Closing and Third Closing will be the lesser of (i) $0.02, subject to certain adjustments for stock splits and other similar transactions, or (ii) 50% of the closing price on the trading day immediately prior to the date of sale. The total number of shares to be sold in the Second Closing and Third Closing will be determined by dividing the total purchase amount of each closing (i.e., $150,000) by the per share purchase price. In each of the Second Closing and Third Closing, Series A Warrants and Series B Warrants will be issued to the Purchasers, both in an amount equal to the number of shares of common stock issued in the closing. The Purchase Agreement limits each Purchaser to beneficial ownership of our common stock of no more than 9.99%. The Purchasers also have certain anti-dilution rights in the Purchase Agreement for a period of 12 months. These rights allow the Purchasers to exchange their shares of common stock received pursuant to the Purchase Agreement for additional shares on the same terms and conditions of a subsequent financing. Registration Rights Agreement On March 30, 2017, we entered into a Registration Rights Agreement with the Purchasers in connection with the Purchase Agreement. In the Registration Rights Agreement, we agreed to prepare and file a registration statement with the Securities and Exchange Commission covering the resale of all of the shares of common stock sold to the Purchasers and the shares issuable upon exercise of the Series A Warrants and Series B Warrants. We agreed to file an initial registration statement as promptly as possible and have it declared effective no later than June 28, 2017 (or July 28, 2017 if the registration statement is reviewed by the Securities and Exchange Commission) and keep it continuously effective until the securities are sold or may be sold under Rule 144 of the Securities Act without volume or manner-of-sale restrictions. If all of the securities cannot be registered on one registration statement, we agreed to file subsequent registration statements to register the remaining securities as promptly as allowed. Common Stock Issuances for Debt Conversions On various dates between January 10, 2017 and March 13, 2017, the Company issued a total of 142,148,242 shares of common stock pursuant to the conversion of an aggregate of $323,197, consisting of $302,480 of principal and $20,717 of interest, among the Second, Fifth and Seventh Redwood Notes. The notes were converted in accordance with the conversion terms; therefore no gain or loss has been recognized. Common Stock Issuances on Stock Purchase Agreement On February 13, 2017, the Company drew down $8,000 on their Stock Purchase Agreement entered into on May 27, 2016, with Redwood and issued 2,000,000 shares of common stock pursuant to the Seventh Put Notice. On January 10, 2017, the Company drew down $10,323 on their Stock Purchase Agreement entered into on May 27, 2016, with Redwood and issued 3,147,110 shares of common stock pursuant to the Sixth Put Notice.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Basis Of Presentation And Significant Accounting Policies Policies
Basis of Presentation	The accompanying unaudited, condensed financial statements of Premier Biomedical, Inc. (“the Company”) have been prepared pursuant to rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, these statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. It is suggested that these statements be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.
Equity Method	Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an Investee depends on an evaluation of several factors including, among others, representation on the Investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the Investee company. Under the equity method of accounting, an Investee company’s accounts are not reflected within the Company’s Balance Sheets and Statements of Operations; however, the Company’s share of the earnings or losses of the Investee company is reflected in the caption “Equity in losses of unconsolidated entity” in the Statements of Operations. The Company’s carrying value in an equity method Investee company is typically reflected in the caption “Investment in Joint Venture.” in the Company’s Balance Sheets. As of June 30, 2017, our share of losses from the investee company exceeded our basis, therefore the investment is not currently presented on the balance sheet. U.S. GAAP considers a change in reporting entity to include “changing specific subsidiaries that make up the group of entities for which consolidated financial statements are presented.” Circumstances may arise where a parent’s controlling financial interest (e.g., generally an ownership interest in excess of 50 percent of the outstanding voting stock) is reduced to a noncontrolling investment that still enables it to exercise significant influence over the operating and financial policies of the investee. A change that results from changed facts and circumstances (such as a partial sale of a subsidiary), where there was only one acceptable method of accounting prior to the change in circumstances (consolidation) and only one acceptable method of accounting after the change (equity method accounting), is not a change in reporting entity and is not be accounted for retrospectively. Accordingly, a change from a controlling interest to a noncontrolling investment accounted for under the equity method is accounted for prospectively from the date of change in control. When the Company’s carrying value in an equity method Investee company is reduced to zero, no further losses are recorded in the Company’s consolidated financial statements unless the Company guaranteed obligations of the Investee company or has committed additional funding. When the Investee company subsequently reports income, the Company will not record its share of such income until it equals the amount of its share of losses not previously recognized.
Nature of Business		Premier Biomedical, Inc. (“the Company”) was incorporated in the State of Nevada on May 10, 2010 (“Inception”). The Company was formed to develop and market medications and procedures that address a significant number of the most highly visible health issues currently affecting mankind. The Company will market these medications and procedures to leading worldwide pharmaceutical firms via publication in medical journals and by direct contact. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	We maintain cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents.	We maintain cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents.
Patent Rights and Applications	Patent rights and applications costs include the acquisition costs and costs incurred for the filing of patents. Patent rights and applications are amortized on a straight-line basis over the legal life of the patent rights beginning at the time the patents are approved. Patent costs for unsuccessful patent applications are expensed when the application is terminated.	Patent rights and applications costs include the acquisition costs and costs incurred for the filing of patents. Patent rights and applications are amortized on a straight-line basis over the legal life of the patent rights beginning at the time the patents are approved. Patent costs for unsuccessful patent applications are expensed when the application is terminated.
Fair Value of Financial Instruments	Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, prepaid expenses and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments.	Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, prepaid expenses and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments.
Basic and Diluted Loss Per Share	The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.	The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.
Stock-Based Compensation	Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company’s stock based compensation consisted of the following during the six months ended June 30, 2017 and 2016, respectively: June 30, June 30, 2017 2016 Common stock issued for services $ - $ 58,800 Warrants issued for services, related parties - 13,014 Warrants issued for services - 17,066 Total stock based compensation $ - $ 88,880	Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company’s stock based compensation consisted of the following during the years ended December 31, 2016 and 2015, respectively: December 31, December 31, 2016 2015 Common stock issued for services $ 70,621 $ - Warrants issued for services, related parties 25,030 1,529,182 Warrants issued for services 14,739 319,986 Total stock based compensation $ 110,390 $ 1,849,168
Revenue Recognition	Sales on fixed price contracts are recorded when services are earned, the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue from sales in which payment has been received, but the earnings process has not occurred. Sales have not yet commenced, other than sales through our joint venture, which our recognized by our joint venture upon shipment of goods, which are paid for at the time of order.	Sales on fixed price contracts are recorded when services are earned, the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue from sales in which payment has been received, but the earnings process has not occurred. Sales have not yet commenced.
Advertising and Promotion	All costs associated with advertising and promoting products are expensed as incurred. These expenses were $25,413 and $51,710 for the six months ended June 30, 2017 and 2016, respectively.	All costs associated with advertising and promoting products are expensed as incurred. These expenses were $82,246 and $59,956 for the years ended December 31, 2016 and 2015, respectively.
Income Taxes	Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.	Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.
Uncertain Tax Positions	In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.	In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.
Recently Issued Accounting Pronouncements	In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350) In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business No other new accounting pronouncements, issued or effective during the six months ended June 30, 2017, have had or are expected to have a significant impact on the Company’s financial statements.	In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350) In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business In December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers Revenue from Contracts with Customers In October 2016, the FASB issued ASU No. 2016-17, Consolidation (Topic 810): Interests Held through Related Parties that are under Common Control In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory In August, 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In June, 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718) . In March, 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date In March, 2016, the FASB issued ASU No. 2016-07, Investments—Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. In March, 2016, the FASB issued ASU No. 2016-04, Liabilities—Extinguishments of Liabilities (Subtopic 405-20): Recognition of Breakage for Certain Prepaid Stored-Value Products No other new accounting pronouncements, issued or effective during the year ended December 31, 2016, have had or are expected to have a significant impact on the Company’s financial statements.

Nature of Business and Signif25

Nature of Business and Significant Accounting Policies (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Nature Of Business And Significant Accounting Policies Tables
Stock-Based Compensation	June 30, June 30, 2017 2016 Common stock issued for services $ - $ 58,800 Warrants issued for services, related parties - 13,014 Warrants issued for services - 17,066 Total stock based compensation $ - $ 88,880	December 31, December 31, 2016 2015 Common stock issued for services $ 70,621 $ - Warrants issued for services, related parties 25,030 1,529,182 Warrants issued for services 14,739 319,986 Total stock based compensation $ 110,390 $ 1,849,168

Restatement (Tables)

Restatement (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Restatement Tables
Restated Balance Sheet:	PREMIER BIOMEDICAL, INC. BALANCE SHEET As Originally Reported As Restated June 30, June 30, 2016 Adjustments 2016 ASSETS Current assets: Cash $ 38,588 $ - $ 38,588 Prepaid expenses 11,545 - 11,545 Total current assets 50,133 - 50,133 Property and equipment, net 6,157 - 6,157 Total assets $ 56,290 $ - $ 56,290 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 143,703 $ - $ 143,703 Accounts payable, related parties 51,298 - 51,298 Accrued interest 22,079 - 22,079 Accrued interest, related parties 2,370 - 2,370 Judgment payable 340,647 - 340,647 Convertible notes payable, net of discounts of $334,869 210,548 (27,283 ) 183,265 Notes payable, related parties 30,000 - 30,000 Derivative liabilities - 507,352 507,352 Total current liabilities 800,645 480,069 1,280,714 Total liabilities 800,645 480,069 1,280,714 Commitments and contingencies - - - Stockholders' equity (deficit): Preferred stock, $0.001 par value, 10,000,000 shares authorized, 2,000,000 shares issued and outstanding 2,000 - 2,000 Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 125,714,852 shares issued and outstanding 1,257 - 1,257 Additional paid in capital 11,167,420 (383,637 ) 10,783,783 Accumulated deficit (11,915,032 ) (96,432 ) (12,011,464 ) Total stockholders' equity (deficit) (744,355 ) (480,069 ) (1,224,424 ) Total liabilities and stockholders' equity (deficit) $ 56,290 $ - $ 56,290	PREMIER BIOMEDICAL, INC. BALANCE SHEET As Originally Reported As Restated December 31, December 31, 2015 Adjustments 2015 ASSETS Current assets: Cash $ 35,414 $ - $ 35,414 Prepaid expenses 9,166 - 9,166 Total current assets 44,580 - 44,580 Property and equipment, net 3,647 - 3,647 Total assets $ 48,227 $ - $ 48,227 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 188,265 $ - $ 188,265 Accounts payable, related parties 54,668 - 54,668 Accrued interest 7,792 - 7,792 Accrued interest, related parties 1,170 - 1,170 Convertible notes payable, net of discounts of $245,345 42,655 (840 ) 41,815 Notes payable, related parties 30,000 - 30,000 Derivative liabilities - 150,076 150,076 Total current liabilities 324,550 149,236 473,786 Total liabilities 324,550 149,236 473,786 Commitments and contingencies - - - Stockholders' equity (deficit): Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 82,331,062 and 21,757,175 shares issued and outstanding at December 31, 2015 and 2014, respectively Additional paid in capital 10,500,651 (130,000 ) 10,370,651 Accumulated deficit (10,777,797 ) (19,236 ) (10,797,033 ) Total stockholders' equity (deficit) (276,323 ) (149,236 ) (425,559 ) Total liabilities and stockholders' equity (deficit) $ 48,227 $ - $ 48,227
Restated Statement of Operations	The following adjustments were made to the Six Months Ended June 30, 2016 Restated Statement of Operations: PREMIER BIOMEDICAL, INC. STATEMENT OF OPERATIONS As Originally Reported As Restated June 30, June 30, 2016 Adjustments 2016 Revenue $ - $ - $ - Operating expenses: Research and development 59,686 - 59,686 General and administrative 91,466 - 91,466 Professional fees 225,959 - 225,959 Total operating expenses 377,111 - 377,111 Net operating loss (377,111 ) - (377,111 ) Other expense: Interest expense (419,477 ) 10,666 (408,811 ) Other expense (340,647 ) - (340,647 ) Change in derivative liabilities - (87,862 ) (87,862 ) Total other expenses (760,124 ) (77,196 ) (837,320 ) Net loss $ (1,137,235 ) $ (77,196 ) $ (1,214,431 ) The following adjustments were made to the Three Months Ended June 30, 2016 Restated Statement of Operations: PREMIER BIOMEDICAL, INC. STATEMENT OF OPERATIONS As Originally Reported As Restated June 30, June 30, 2016 Adjustments 2016 Revenue $ - $ - $ - Operating expenses: Research and development 49,545 - 49,545 General and administrative 41,981 - 41,981 Professional fees 87,511 - 87,511 Total operating expenses 179,037 - 179,037 Net operating loss (179,037 ) - (179,037 ) Other expense: Interest expense (202,402 ) (33,122 ) (235,524 ) Other expense (340,647 ) - (340,647 ) Change in derivative liabilities - (189,191 ) (189,191 ) Total other expenses (543,049 ) (222,313 ) (765,362 ) Net loss $ (722,086 ) $ (222,313 ) $ (944,399 )	PREMIER BIOMEDICAL, INC. STATEMENT OF OPERATIONS As Originally Reported As Restated December 31, December 31, 2015 Adjustments 2015 Revenue $ - $ - $ - Operating expenses: Research and development 234,095 - 234,095 General and administrative 133,289 - 133,289 Professional fees 2,015,898 - 2,015,898 Total operating expenses 2,383,282 - 2,383,282 Net operating loss (2,383,282 ) - (2,383,282 ) Other expense: Interest expense (198,889 ) 840 (198,049 ) Change in derivative liabilities - (20,076 ) (20,076 ) Total other expenses (198,889 ) (19,236 ) (218,125 ) Net loss $ (2,582,171 ) $ (19,236 ) $ (2,601,407 )
Restated Stockholders' Equity		PREMIER BIOMEDICAL, INC. SUMMARY OF CORRECTIONS TO STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) As Originally Reported As Restated December 31, December 31, 2015 Adjustments 2015 Beneficial conversion feature of convertible note $ 297,011 $ (130,000 ) $ 167,011 Additional Paid-In Capital $ 10,500,651 $ (130,000 ) $ 10,370,651 Net loss for the year ended December 31, 2015 $ (2,582,171 ) $ (19,236 ) $ (2,601,407 ) Accumulated Deficit $ (10,777,797 ) $ (19,236 ) $ (10,797,033 )
Restated Statement of Cash Flows	PREMIER BIOMEDICAL, INC. STATEMENT OF CASH FLOWS As Originally Reported As Restated June 30, June 30, 2016 Adjustments 2016 CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ (1,137,235 ) $ (77,196 ) $ (1,214,431 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 1,026 - 1,026 Change in fair market value of derivative liabilities - 87,862 87,862 Amortization of debt discounts 383,229 (10,666 ) 372,563 Stock based compensation, related parties 13,014 - 13,014 Stock based compensation 75,866 - 75,866 Decrease (increase) in assets: Prepaid expenses (2,379 ) - (2,379 ) Increase (decrease) in liabilities: Accounts payable (44,562 ) - (44,562 ) Accounts payable, related parties 10,395 - 10,395 Accrued interest 35,048 - 35,048 Accrued interest, related parties 1,200 - 1,200 Judgment payable 340,647 - 340,647 Net cash used in operating activities (323,751 ) - (323,751 ) CASH FLOWS FROM INVESTING ACTIVITIES Purchases of property and equipment (3,536 ) - (3,536 ) Net cash used in investing activities (3,536 ) - (3,536 ) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from exercise of warrants, related party 2,000 - 2,000 Proceeds from convertible notes payable 417,500 - 417,500 Repayments from convertible notes payable (89,039 ) - (89,039 ) Net cash provided by financing activities 330,461 - 330,461 NET CHANGE IN CASH 3,174 - 3,174 CASH AT BEGINNING OF PERIOD 35,414 - 35,414 CASH AT END OF PERIOD $ 38,588 $ - $ 38,588 SUPPLEMENTAL INFORMATION: Interest paid $ 13,539 $ - $ 13,539 Income taxes paid $ - $ - $ - NON-CASH INVESTING AND FINANCING ACTIVITIES: Discount on beneficial conversion feature on convertible note $ 364,220 $ (364,220 ) $ - Value of debt discounts $ - $ 110,583 $ 110,583 Value of shares issued for conversion of debt $ 200,338 $ - $ 200,338 Cashless exercise of common stock warrants $ 22 $ - $ 22 Common stock issued for settlement of accounts payable $ 13,765 $ - $ 13,765	PREMIER BIOMEDICAL, INC. STATEMENT OF CASH FLOWS As Originally Reported As Restated December 31, December 31, 2015 Adjustments 2015 CASH FLOWS FROM OPERATING ACTIVITIES Net (loss) $ (2,582,171 ) $ (19,236 ) $ (2,601,407 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 1,462 - 1,462 Change in fair market value of derivative liabilities - 20,076 20,076 Amortization of debt discounts 176,547 (840 ) 175,707 Stock based compensation, related parties 1,529,182 - 1,529,182 Stock based compensation 319,986 - 319,986 Decrease (increase) in assets: Prepaid expenses 284 - 284 Increase (decrease) in liabilities: Accounts payable 40,774 - 40,774 Accounts payable, related parties 29,369 - 29,369 Accrued interest 21,172 - 21,172 Accrued interest, related parties 1,170 - 1,170 Net cash used in operating activities (462,225 ) - (462,225 ) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from exercise of warrants, related party 40 - 40 Proceeds from convertible notes payable 365,000 - 365,000 Proceeds from notes payable, related parties 30,000 - 30,000 Net cash provided by financing activities 395,040 - 395,040 NET CHANGE IN CASH (67,185 ) - (67,185 ) CASH AT BEGINNING OF PERIOD 102,599 - 102,599 CASH AT END OF PERIOD $ 35,414 $ - $ 35,414 SUPPLEMENTAL INFORMATION: Interest paid $ - $ - $ - Income taxes paid $ - $ - $ - NON-CASH INVESTING AND FINANCING ACTIVITIES: Discount on beneficial conversion feature on convertible note $ 297,011 $ (130,000 ) $ 167,011 Value of debt discounts $ - $ 130,000 $ 130,000 Value of shares issued for conversion of debt $ 227,388 $ - $ 227,388

Fair Value of Financial Instr27

Fair Value of Financial Instruments (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Fair Value Of Financial Instruments Tables
Fair Value of Financial Instruments	The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2017 and December 31, 2016, respectively: Fair Value Measurements at June 30, 2017 Level 1 Level 2 Level 3 Assets Cash $ 125,341 $ - $ - Total assets 125,341 - - Liabilities Notes payable, related parties - 30,000 - Derivative liabilities - - 6,253,880 Total liabilities - 30,000 6,253,880 $ 125,341 $ (30,000 ) $ (6,253,880 ) Fair Value Measurements at December 31, 2016 Level 1 Level 2 Level 3 Assets Cash $ 22,437 $ - $ - Total assets 22,437 - - Liabilities Convertible note payable, net of discounts - 153,024 - Notes payable, related parties 30,000 - Derivative liabilities - - 221,822 Total liabilities - 183,024 221,822 $ 22,437 $ (183,024 ) $ (221,822 )	Fair Value Measurements at December 31, 2016 Level 1 Level 2 Level 3 Assets Cash $ 22,437 $ - $ - Total assets 22,437 - - Liabilities Convertible note payable, net of discounts - 153,024 - Notes payable, related parties - 30,000 - Total liabilities - 183,024 - $ 22,437 $ (183,024 ) $ - Fair Value Measurements at December 31, 2015 Level 1 Level 2 Level 3 Assets Cash $ 35,414 $ - $ - Total assets 35,414 - - Liabilities Convertible note payable, net of discounts - 41,815 - Notes payable, related parties - 30,000 - Total liabilities - 71,815 - $ 35,414 $ (71,815 ) $ -

Convertible Note Payable (Table

Convertible Note Payable (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Convertible Note Payable Tables
Summary of convertible note payable	June 30, December 31, 2017 2016 On October 10, 2016, the Company issued a 10% interest bearing; unsecured convertible promissory note with a face value of $300,000 (“Seventh Redwood Note”), which matures on October 10, 2017, pursuant to a Warrant Purchase Agreement by and among Redwood Management, LLC, the Company and Typenex. Pursuant to this agreement, Redwood purchased the warrants from Typenex, and Typenex provided a Satisfaction of Judgment and Release of Garnishment to release the Writ of Garnishment Typenex had placed on our transfer agent. Redwood paid installment payments to Typenex in the aggregate amount of $300,000, which were completed on, or about November 10, 2016. The principal and interest of the Seventh Redwood Note is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. This settled the dispute with Typenex. A total of $308,750, consisting of $300,000 of principal and $8,750 of interest, was converted into 135,596,882 shares of common stock on various dates between November 21, 2016 and February 24, 2017. $ - $ 275,000 On March 11, 2016, the Company received net proceeds of $90,000 in exchange for a 10% interest bearing; unsecured convertible promissory note with a face value of $105,000 (“Fifth Redwood Note”), which matures on December 11, 2016. The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. A total of $120,517, consisting of $105,000 of principal and $15,517 of interest, was converted into an aggregate of 47,820,025 shares of common stock at various dates between November 8, 2016 and March 13, 2017. - 27,480 Total convertible notes payable - 302,480 Less unamortized derivative discounts: - 149,456 Convertible notes payable - 153,024 Less: current portion - 153,024 Convertible notes payable, less current portion $ - $ -	December 31, December 31, 2016 2015 On October 10, 2016, the Company issued a 10% interest bearing; unsecured convertible promissory note with a face value of $300,000 (“Seventh Redwood Note”), which matures on October 10, 2017, pursuant to a Warrant Purchase Agreement by and among Redwood Management, LLC, the Company and Typenex. Pursuant to this agreement, Redwood purchased the warrants from Typenex, and Typenex provided a Satisfaction of Judgment and Release of Garnishment to release the Writ of Garnishment Typenex had placed on our transfer agent. Redwood paid installment payments to Typenex in the aggregate amount of $300,000, which were completed on, or about November 10, 2016. The principal and interest of the Seventh Redwood Note is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. This settled the dispute with Typenex. A total of $25,000 of principal was converted into 8,620,690 shares of common stock on November 21, 2016. $ 275,000 $ - On May 27, 2016, the Company received net proceeds of $85,000 in exchange for a 10% interest bearing; unsecured convertible promissory note with a face value of $105,000 (“Sixth Redwood Note”), which matures on February 27, 2017. The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. A total of $106,879, consisting of $105,000 of principal and $1,879 of interest, was converted into an aggregate of 20,039,892 shares of common stock at various dates between July 13, 2016 and December 7, 2016. - - On March 11, 2016, the Company received net proceeds of $90,000 in exchange for a 10% interest bearing; unsecured convertible promissory note with a face value of $105,000 (“Fifth Redwood Note”), which matures on December 11, 2016. The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. A total of $81,070, consisting of $77,520 of principal and $3,550 of interest, was converted into an aggregate of 32,647,975 shares of common stock at various dates between November 8, 2016 and December 22, 2016. 27,480 - On March 7, 2016, the Company received net proceeds of $67,500 in exchange for a 10% interest bearing; unsecured convertible promissory note with a face value of $78,750 (“Fourth Redwood Note”), which matures on December 7, 2016. The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. A total of $83,930, consisting of $78,750 of principal and $5,180 of interest, was converted into an aggregate of 20,628,179 shares of common stock at various dates between October 26, 2016 and December 7, 2016. - - On February 24, 2016, the Company received net proceeds of $67,500 in exchange for a 10% interest bearing; unsecured convertible promissory note dated February 22, 2016 with a face value of $78,750 (“Third Redwood Note”), which matures on November 22, 2016. The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. A total of $83,357, consisting of $78,750 of principal and $4,607 of interest, was converted into an aggregate of 17,926,514 shares of common stock at various dates between August 26, 2016 and December 7, 2016. - - On January 8, 2016, the Company received net proceeds of $107,500 in exchange for a 10% interest bearing; unsecured convertible promissory note with a face value of $131,250 (“Second Redwood Note”), which matures on October 8, 2016. The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. A total of $131,250 of principal was converted into an aggregate of 23,360,868 shares of common stock at various dates between July 11, 2016 and August 1, 2016. - - On December 28, 2015, the Company received net proceeds of $130,000 in exchange for a 10% interest bearing; unsecured convertible promissory note dated December 28, 2015 with a face value of $157,500 (“First Redwood Note”), which matures on September 28, 2016. The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. A total of $164,007, consisting of $157,500 of principal and $6,507 of interest, was converted into an aggregate of 29,612,923 shares of common stock at various dates between April 6, 2016 and December 7, 2016. - 157,500 On December 15, 2015, the Company received net proceeds of $25,000 in exchange for a non-interest bearing, unsecured convertible promissory note with a face value of $27,500 (“Second JMJ Note”), which matures on December 15, 2016, as part of a larger financing agreement that enables the Company to draw total proceeds of $250,000 at the discretion of the lender. The principal and interest was convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of sixty percent (60%) of the lowest trading price of the Company’s common stock over the twenty five (25) trading days prior to the conversion request date, or a fixed rate of $0.00005 per share, as amended within the original promissory note on September 8, 2015 (In the case that conversion shares are not deliverable by DWAC an additional 10% discount will apply; and if the shares are ineligible for deposit into the DTC system and only eligible for Xclearing deposit an additional 5% discount shall apply; in the case of both an additional cumulative 15% discount shall apply). The note carries a one-time twelve percent (12%) of principal interest charge in the event of default, and the debt holder is limited to owning 4.99% of the Company’s issued and outstanding shares. The promissory note carried a $2,500 Original Issue Discount that was being amortized over the life of the loan on the straight line method, which approximates the effective interest method. The Company reserved at least 24 million shares of common stock for potential conversions. The note was paid in full on March 4, 2016 out of the proceeds from the Redwood Notes. - 27,500 On September 21, 2015, the Company received net proceeds of $45,000 in exchange for an 8% interest bearing; unsecured convertible promissory note dated September 3, 2015 with a face value of $48,000 (“First Vis Vires Note”), which matures on June 8, 2016. The principal and interest was convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of fifty eight percent (58%) of the average of the three (3) lowest closing bid prices over the 10 days prior to conversion, or a fixed rate of $0.00001 per share. The note included various prepayment penalties ranging from 112% through 130%, and default provisions of 150% of the then outstanding principal and interest, and an interest rate of 22% thereafter. The debt holder was limited to owning 4.99% of the Company’s issued and outstanding shares. The Company must at all times reserve at least 20,250,000 shares of common stock for potential conversions. The note was paid in full on January 19, 2016 out of the proceeds from the Redwood Notes. - 48,000 On September 2, 2015, the Company received net proceeds of $50,000 in exchange for a non-interest bearing, unsecured convertible promissory note with a face value of $55,000 (“First JMJ Note”), which matures on September 1, 2016, as part of a larger financing agreement that enables the Company to draw total proceeds of $250,000 at the discretion of the lender. The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of sixty percent (60%) of the lowest trading price of the Company’s common stock over the twenty five (25) trading days prior to the conversion request date, or a fixed rate of $0.00005 per share, as amended within the original promissory note on September 8, 2015 (In the case that conversion shares are not deliverable by DWAC an additional 10% discount will apply; and if the shares are ineligible for deposit into the DTC system and only eligible for Xclearing deposit an additional 5% discount shall apply; in the case of both an additional cumulative 15% discount shall apply). The note carries a one-time twelve percent (12%) of principal interest charge in the event of default, and the debt holder is limited to owning 4.99% of the Company’s issued and outstanding shares. The promissory note carries a $5,000 Original Issue Discount that is being amortized over the life of the loan on the straight line method, which approximates the effective interest method. The Company reserved at least 24 million shares of common stock for potential conversions. A total of $62,222, consisting of $55,000 of principal and $7,222 of interest, was converted into an aggregate of 12,359,944 shares of common stock at various dates between March 2, 2016 and April 19, 2016. - 55,000 Total convertible notes payable 302,480 288,000 Less unamortized debt discounts: Derivative discounts 149,456 129,422 Discounts on beneficial conversion feature - 81,648 Original issue discounts - 13,164 Loan origination discounts - 21,951 Convertible notes payable 153,024 41,815 Less: current portion 153,024 41,815 Convertible notes payable, less current portion $ - $ -
Interest expense related to the convertible debts		December 31, December 31, 2016 2015 Interest on judgment payable $ 13,141 $ - Interest on convertible notes 52,720 21,172 Interest on related party loans 2,400 1,170 Amortization of derivative discounts 551,149 578 Amortization of loan origination costs 79,451 10,272 Amortization of beneficial conversion feature 81,648 117,500 Amortization of OID 36,914 14,384 Amortization of warrants issued with convertible notes - 32,973 Total interest expense $ 817,423 $ 198,049
Recognized interest expense	June 30, June 30, 2017 2016 Interest on convertible notes $ 2,691 $ 35,048 Interest on related party loans 1,200 1,200 Amortization of beneficial conversion feature - 81,648 Amortization of OID - 20,647 Amortization of loan origination costs - 44,811 Derivative discounts 149,456 225,457 Total interest expense $ 153,347 $ 408,811	December 31, December 31, 2016 2015 Derivative discounts $ 571,183 $ 130,000 Beneficial conversion feature discounts - 167,011 Original issue discounts 23,750 21,037 Loan origination costs 57,500 28,750 Total debt discounts $ 652,433 $ 346,798

Other Current Assets (Tables)

Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Summary of other current assets	June 30, December 31, 2017 2016 Deposit on inventory purchase $ 52,100 $ - Other receivable, related party 48,778 - Prepaid expenses 17,743 11,430 $ 141,521 $ 11,430

Notes Payable, Related Parties

Notes Payable, Related Parties (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Notes Payable Related Parties Tables
Notes payable, related parties	June 30, December 31, 2017 2016 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s CEO. $ 10,000 $ 10,000 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s Chairman of the Board. 10,000 10,000 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from one of the Company’s Directors. 10,000 10,000 Total notes payable, related parties 30,000 30,000 Less: current portion 30,000 30,000 Notes payable, related parties, less current portion $ - $ -	December 31, December 31, 2016 2015 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s CEO. $ 10,000 $ 10,000 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s Chairman of the Board. 10,000 10,000 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from one of the Company’s Directors. 10,000 10,000 Total notes payable, related parties 30,000 30,000 Less: current portion 30,000 30,000 Notes payable, related parties, less current portion $ - $ -

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Derivative Liabilities Tables
Summary of Changes in fair market value Derivative Liability	Derivative Liability Total Balance, December 31, 2015 $ 150,076 Increase in derivative value due to issuances of convertible promissory notes 583,415 Change in fair market value of derivative liabilities due to the mark to market adjustment 13,816 Debt conversions (525,485 ) Balance, December 31, 2016 $ 221,822 Increase in derivative value due to issuances of warrants 7,103,444 Change in fair market value of derivative liabilities due to the mark to market adjustment (842,343 ) Debt conversions (229,043 ) Balance, June 30, 2017 $ 6,253,880	Derivative Liability Total Balance, December 31, 2014 $ - Increase in derivative value due to issuances of convertible promissory notes 144,748 Change in fair market value of derivative liabilities due to the mark to market adjustment 5,328 Debt conversions - Balance, December 31, 2015 $ 150,076 Increase in derivative value due to issuances of convertible promissory notes 583,415 Change in fair market value of derivative liabilities due to the mark to market adjustment 13,816 Debt conversions (525,485 ) Balance, December 31, 2016 $ 221,822

Series A Convertible Preferre32

Series A Convertible Preferred Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2016
Series Convertible Preferred Stock Warrants Tables
Summary of Activity outstanding series A Preferred stock warrants	Weighted Average Number of Exercise Shares Price Balance, December 31, 2014 2,000,000 $ 0.001 Warrants expired - - Warrants granted - - Warrants exercised - - Balance, December 31, 2015 2,000,000 $ 0.001 Warrants expired - - Warrants granted - - Warrants exercised (2,000,000 ) (0.001 ) Balance, December 31, 2016 - $ - Exercisable, December 31, 2016 - $ -

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2016
Common Stock Warrants Tables
Summary of information Common Stock Warrants outstanding	Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $ 0.00001 – $1.45 30,690,000 4.91 years $ 0.24407 30,690,000 $ 0.24407
fair value of warrant grant is estimated weighted Average Assumptions	December 31, December 31, 2016 2015 Average risk-free interest rates N/A 1.75 % Average expected life (in years) N/A 9.22
Summary of Activity Outstanding Common stock warrants	Weighted Average Number of Exercise Shares Price Balance, December 31, 2014 50,591,455 $ 0.1443 Warrants expired (50,000 ) (0.25 ) Warrants granted 7,050,000 0.0784 Warrants exercised (4,000,000 ) (0.00001 ) Balance, December 31, 2015 53,591,455 $ 0.1463 Warrants cancelled (351,455 ) (0.18 ) Warrants expired (300,000 ) (0.96 ) Warrants exercised (22,250,000 ) (0.00001 ) Balance, December 31, 2016 30,690,000 $ 0.24407 Exercisable, December 31, 2016 30,690,000 $ 0.24407

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Income Taxes Tables
Deferred tax asset	June 30, December 31, 2017 2016 Deferred tax assets: Net operating loss carry forwards $ 1,629,600 $ 1,516,900 Net deferred tax assets before valuation allowance $ 1,629,600 $ 1,516,900 Less: Valuation allowance (1,629,600 ) (1,516,900 ) Net deferred tax assets $ - $ -	December 31, December 31, 2016 2015 Deferred tax assets: Net operating loss carry forwards $ 1,516,900 $ 932,050 Net deferred tax assets before valuation allowance $ 1,516,900 $ 932,050 Less: Valuation allowance (1,516,900 ) (932,050 ) Net deferred tax assets $ - $ -
Reconciliation between the amounts of income tax	June 30, December 31, 2017 2016 Federal and state statutory rate 35 % 35 % Change in valuation allowance on deferred tax assets (35 %) (35%)	December 31, December 31, 2016 2015 Federal and state statutory rate 35 % 35 % Change in valuation allowance on deferred tax assets (35 %) (35 %)

Nature of Business and Signif35

Nature of Business and Significant Accounting Policies (Details) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Nature Of Business And Significant Accounting Policies Details
Common stock issued for services		$ 58,800	$ 70,621
Warrants issued for services, related parties		13,014	25,030	1,529,182
Warrants issued for services		17,066	14,739	319,986
Total stock based compensation		$ 88,880	$ 110,390	$ 1,849,168

Nature of Business and Signif36

Nature of Business and Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
State of Incorporation	Nevada
Date of Incorporation	May 10, 2010
Advertising and promotion expenses	$ 25,413	$ 51,710	$ 82,246	$ 59,956
Minimum [Member]
Ownership	20.00%
Maximum [Member]
Ownership	50.00%

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Going Concern Details Narrative
Accumulated deficit	$ (19,141,821)	$ (12,565,254)	$ (10,797,033)
Working capital deficit	$ (6,238,311)	$ (665,804)

Restatement (Details)

Restatement (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash	$ 125,341	$ 22,437		$ 35,414
Prepaid Expenses		11,430		9,166
Total current assets	266,862	33,867		44,580
Property and equipment, net	6,603	5,100		3,647
Total assets	273,465	38,967		48,227
Current liabilities:
Accounts Payable	163,087	220,740		188,265
Accounts payable, related parties	53,436	52,489		54,668
Accrued interest		18,026		7,792
Accrued interest, related parties	4,770	3,570		1,170
Convertible notes payable, net of discounts of $334,869		153,024		41,815
Notes payable, related parties	30,000	30,000		30,000
Derivative liabilities	6,253,880	221,822		150,076
Total current liabilities	6,505,173	699,671		473,786
Total liabilities	6,505,173	699,671		473,786
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 2,000,000 shares issued and outstanding	2,000	2,000
Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 125,714,852 shares issued and outstanding	5,222	3,046		823
Additional paid in capital	12,902,891	11,899,504		10,370,651
Accumulated deficit	(19,141,821)	(12,565,254)		(10,797,033)
Total stockholders' equity (deficit)	(6,231,708)	(660,704)		(425,559)	$ (67,759)
Total liabilities and stockholders' equity (deficit)	$ 273,465	$ 38,967		48,227
As Originally Reported [Member]
Current assets:
Cash			$ 38,588	35,414
Prepaid Expenses			11,545	9,166
Total current assets			50,133	44,580
Property and equipment, net			6,157	3,647
Total assets			56,290	48,227
Current liabilities:
Accounts Payable			143,703	188,265
Accounts payable, related parties			51,298	54,668
Accrued interest			22,079	7,792
Accrued interest, related parties			2,370	1,170
Judgment payable			340,647
Convertible notes payable, net of discounts of $334,869			210,548	42,655
Notes payable, related parties			30,000	30,000
Derivative liabilities
Total current liabilities			800,645	324,550
Total liabilities			800,645	324,550
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 2,000,000 shares issued and outstanding			2,000
Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 125,714,852 shares issued and outstanding			1,257	823
Additional paid in capital			11,167,420	10,500,651
Accumulated deficit			(11,915,032)	(10,777,797)
Total stockholders' equity (deficit)			(744,355)	(276,323)
Total liabilities and stockholders' equity (deficit)			56,290	48,227
Adjustment [Member]
Current assets:
Cash
Prepaid Expenses
Total current assets
Property and equipment, net
Total assets
Current liabilities:
Accounts Payable
Accounts payable, related parties
Accrued interest
Accrued interest, related parties
Judgment payable
Convertible notes payable, net of discounts of $334,869			(27,283)	(840)
Notes payable, related parties
Derivative liabilities			507,352	150,076
Total current liabilities			480,069	149,236
Total liabilities			480,069	149,236
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 2,000,000 shares issued and outstanding
Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 125,714,852 shares issued and outstanding
Additional paid in capital			(383,637)	(130,000)
Accumulated deficit			(96,432)	(19,236)
Total stockholders' equity (deficit)			(480,069)	(149,236)
Total liabilities and stockholders' equity (deficit)
As Restated [Member]
Current assets:
Cash			38,588	35,414
Prepaid Expenses			11,545	9,166
Total current assets			50,133	44,580
Property and equipment, net			6,157	3,647
Total assets			56,290	48,227
Current liabilities:
Accounts Payable			143,703	188,265
Accounts payable, related parties			51,298	54,668
Accrued interest			22,079	7,792
Accrued interest, related parties			2,370	1,170
Judgment payable			340,647
Convertible notes payable, net of discounts of $334,869			183,265	41,815
Notes payable, related parties			30,000	30,000
Derivative liabilities			507,352	150,076
Total current liabilities			1,280,714	473,786
Total liabilities			1,280,714	473,786
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 2,000,000 shares issued and outstanding			2,000
Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 125,714,852 shares issued and outstanding			1,257	823
Additional paid in capital			10,783,783	10,370,651
Accumulated deficit			(12,011,464)	(10,797,033)
Total stockholders' equity (deficit)			(1,224,424)	(425,559)
Total liabilities and stockholders' equity (deficit)			$ 56,290	$ 48,227

Restatement (Details 1)

Restatement (Details 1) - USD ($)	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Revenue
Operating expenses:
Research and development				113,862	234,095
General and administrative		73,305		191,379	133,289
Professional fees		86,756		332,650	2,015,898
Total operating expenses		160,061		637,891	2,383,282
Net operating loss		(160,061)		(637,891)	(2,383,282)
Other expense:
Interest expense		153,347		817,423	198,049
Change in derivative liabilities		(6,261,101)	$ 87,862	(26,048)	(20,076)
Total other expenses		(6,416,506)		(1,130,330)	(218,125)
Net loss		$ (6,576,567)		$ (1,768,221)	(2,601,407)
As Originally Reported [Member]
Revenue
Operating expenses:
Research and development	49,545		59,686		234,095
General and administrative	41,981		91,466		133,289
Professional fees	87,511		225,959		2,015,898
Total operating expenses	179,037		377,111		2,383,282
Net operating loss	(179,037)		(377,111)		(2,383,282)
Other expense:
Interest expense	(202,402)		(419,477)		(198,889)
Other expense	(340,647)		(340,647)
Change in derivative liabilities
Total other expenses	(543,049)		(760,124)		(198,889)
Net loss	(722,086)		(1,137,235)		(2,582,171)
Adjustment [Member]
Revenue
Operating expenses:
Research and development
General and administrative
Professional fees
Total operating expenses
Net operating loss
Other expense:
Interest expense	(33,122)		10,666		840
Other expense
Change in derivative liabilities	(189,191)		(87,862)		(20,076)
Total other expenses	(222,313)		(77,196)		(19,236)
Net loss	(222,313)		(77,196)		(19,236)
As Restated [Member]
Revenue
Operating expenses:
Research and development	49,545		59,686		234,095
General and administrative	41,981		91,466		133,289
Professional fees	87,511		225,959		2,015,898
Total operating expenses	179,037		377,111		2,383,282
Net operating loss	(179,037)		(377,111)		(2,383,282)
Other expense:
Interest expense	(235,524)		(408,811)		(198,049)
Other expense	(340,647)		(340,647)
Change in derivative liabilities	(189,191)		(87,862)		(20,076)
Total other expenses	(765,362)		(837,320)		(218,125)
Net loss	$ (944,399)		$ (1,214,431)		$ (2,601,407)

Restatement (Details 2)

Restatement (Details 2) - USD ($)	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Beneficial conversion feature of convertible note					$ 167,011
Net loss for the year ended December 31, 2015		$ (6,576,567)		$ (1,768,221)	(2,601,407)
Accumulated Deficit		$ (19,141,821)		$ (12,565,254)	(10,797,033)
As Originally Reported [Member]
Beneficial conversion feature of convertible note					297,011
Additional Paid-In Capital					10,500,651
Net loss for the year ended December 31, 2015	$ (722,086)		$ (1,137,235)		(2,582,171)
Accumulated Deficit	(11,915,032)		(11,915,032)		(10,777,797)
Adjustment [Member]
Beneficial conversion feature of convertible note					(130,000)
Additional Paid-In Capital					(130,000)
Net loss for the year ended December 31, 2015	(222,313)		(77,196)		(19,236)
Accumulated Deficit	(96,432)		(96,432)		(19,236)
As Restated [Member]
Beneficial conversion feature of convertible note					167,011
Additional Paid-In Capital					10,370,651
Net loss for the year ended December 31, 2015	(944,399)		(1,214,431)		(2,601,407)
Accumulated Deficit	$ (12,011,464)		$ (12,011,464)		$ (10,797,033)

Restatement (Details 3)

Restatement (Details 3) - USD ($)	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		$ (6,576,567)		$ (1,768,221)	$ (2,601,407)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		1,191		2,083	1,462
Change in fair market value of derivative liabilities		6,261,101	$ (87,862)	26,048	20,076
Amortization of debt discount		149,456		749,162	175,707
Stock based compensation, related parties				25,030	1,529,182
Stock based compensation				85,360	319,986
Decrease (increase) in assets:
Prepaid expenses				(2,264)	284
Increase (decrease) in liabilities:
Accounts payable		(57,653)		32,475	40,774
Accounts payable, related parties		947		11,586	29,369
Accrued interest		2,691		65,860	21,172
Accrued interest, related parties		1,200	1,200	2,400	1,170
Net cash used in operating activities		(345,667)		(483,622)	(462,225)
CASH FLOWS FROM INVESTING ACTIVITIES
Net cash used in investing activities		(4,752)		(3,536)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of warrants, related party				2,200	40
Proceeds of convertible notes payable				417,500	365,000
Proceeds of notes payable, related parties					30,000
Net cash provided by financing activities		453,323		474,181	395,040
NET CHANGE IN CASH		102,904		(12,977)	(67,185)
CASH AT BEGINNING OF PERIOD		22,437	35,414	35,414	102,599
CASH AT END OF PERIOD		125,341		22,437	35,414
SUPPLEMENTAL INFORMATION:
Interest paid				13,539
Income taxes paid
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Discount on beneficial conversion feature on convertible note					167,011
Value of debt discounts				571,183	130,000
Value of shares issued for conversion of debt		323,197		737,716	227,388
Cashless exercise of common stock warrants				22
Common stock issued for settlement of accounts payable				13,765
As Originally Reported [Member]
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (722,086)		(1,137,235)		(2,582,171)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation			1,026		1,462
Change in fair market value of derivative liabilities
Amortization of debt discount			383,229		176,547
Stock based compensation, related parties			13,014		1,529,182
Stock based compensation			75,866		319,986
Decrease (increase) in assets:
Prepaid expenses			(2,379)		284
Increase (decrease) in liabilities:
Accounts payable			(44,562)		40,774
Accounts payable, related parties			10,395		29,369
Accrued interest			35,048		21,172
Accrued interest, related parties			1,200		1,170
Judgment payable			340,647
Net cash used in operating activities			(323,751)		(462,225)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment			(3,536)
Net cash used in investing activities			(3,536)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of warrants, related party			2,000		40
Proceeds of convertible notes payable			417,500		365,000
Repayments from convertible notes payable			(89,039)
Proceeds of notes payable, related parties					30,000
Net cash provided by financing activities			330,461		395,040
NET CHANGE IN CASH			3,174		(67,185)
CASH AT BEGINNING OF PERIOD			35,414	35,414	102,599
CASH AT END OF PERIOD	38,588		38,588		35,414
SUPPLEMENTAL INFORMATION:
Interest paid			13,539
Income taxes paid
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Discount on beneficial conversion feature on convertible note			364,220		297,011
Value of debt discounts
Value of shares issued for conversion of debt			200,338		227,388
Cashless exercise of common stock warrants			22
Common stock issued for settlement of accounts payable			13,765
Adjustment [Member]
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	(222,313)		(77,196)		(19,236)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Change in fair market value of derivative liabilities	189,191		87,862		20,076
Amortization of debt discount			(10,666)		(840)
Stock based compensation, related parties
Stock based compensation
Decrease (increase) in assets:
Prepaid expenses
Increase (decrease) in liabilities:
Accounts payable
Accounts payable, related parties
Accrued interest
Accrued interest, related parties
Judgment payable
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of warrants, related party
Proceeds of convertible notes payable
Repayments from convertible notes payable
Proceeds of notes payable, related parties
Net cash provided by financing activities
NET CHANGE IN CASH
CASH AT BEGINNING OF PERIOD
CASH AT END OF PERIOD
SUPPLEMENTAL INFORMATION:
Interest paid
Income taxes paid
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Discount on beneficial conversion feature on convertible note			(364,220)		(130,000)
Value of debt discounts			110,583		130,000
Value of shares issued for conversion of debt
Cashless exercise of common stock warrants
Common stock issued for settlement of accounts payable
As Restated [Member]
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	(944,399)		(1,214,431)		(2,601,407)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation			1,026		1,462
Change in fair market value of derivative liabilities	189,191		87,862		20,076
Amortization of debt discount			372,563		175,707
Stock based compensation, related parties			13,014		1,529,182
Stock based compensation			75,866		319,986
Decrease (increase) in assets:
Prepaid expenses			(2,379)		284
Increase (decrease) in liabilities:
Accounts payable			(44,562)		40,774
Accounts payable, related parties			10,395		29,369
Accrued interest			35,048		21,172
Accrued interest, related parties			1,200		1,170
Judgment payable			340,647
Net cash used in operating activities			(323,751)		(462,225)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment			(3,536)
Net cash used in investing activities			(3,536)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of warrants, related party			2,000		40
Proceeds of convertible notes payable			417,500		365,000
Repayments from convertible notes payable			(89,039)
Proceeds of notes payable, related parties					30,000
Net cash provided by financing activities			330,461		395,040
NET CHANGE IN CASH			3,174		(67,185)
CASH AT BEGINNING OF PERIOD			35,414	$ 35,414	102,599
CASH AT END OF PERIOD	$ 38,588		38,588		35,414
SUPPLEMENTAL INFORMATION:
Interest paid			13,539
Income taxes paid
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Discount on beneficial conversion feature on convertible note					167,011
Value of debt discounts			110,583		130,000
Value of shares issued for conversion of debt			200,338		$ 227,388
Cashless exercise of common stock warrants			22
Common stock issued for settlement of accounts payable			$ 13,765

Restatement (Details Narrative)

Restatement (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Accumulated Deficit		$ (19,141,821)		$ (12,565,254)	$ (10,797,033)
Net loss for the year ended December 31, 2015		$ (6,576,567)		$ (1,768,221)	(2,601,407)
As Originally Reported [Member]
Accumulated Deficit	$ (11,915,032)		$ (11,915,032)		(10,777,797)
Net loss for the year ended December 31, 2015	(722,086)		(1,137,235)		(2,582,171)
Additional Paid-In Capital					10,500,651
Adjustment [Member]
Accumulated Deficit	(96,432)		(96,432)		(19,236)
Net loss for the year ended December 31, 2015	(222,313)		(77,196)		(19,236)
Additional Paid-In Capital					(130,000)
As Restated [Member]
Accumulated Deficit	(12,011,464)		(12,011,464)		(10,797,033)
Net loss for the year ended December 31, 2015	$ (944,399)		$ (1,214,431)		(2,601,407)
Additional Paid-In Capital					$ 10,370,651

Related Party (Details Narrativ

Related Party (Details Narrative) - USD ($)	Oct. 07, 2015	Oct. 07, 2015	Sep. 10, 2015	Oct. 19, 2016	Mar. 28, 2016	Jan. 29, 2016	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015	Oct. 07, 2016	Jul. 06, 2015
Other receivable, related party							$ 48,778
Exercise price of warrants		$ 0.05
Foregoing warrants excercise price	$ 0.05	$ 0.05
Warrants exercisable	10 years
Common stock warrants	3,750,000	3,750,000					1,250,000	1,250,000
Common stock fair value	$ 31,109	$ 31,109
Option-pricing per share	$ 0.0083	$ 0.0083
Volatility rate	232.00%	232.00%
Risk-free interest rate	1.75%	1.75%							1.75%
Expected term	10 years	10 years						0 years	9 years 2 months 19 days
Stock-based compensation								$ 25,030	$ 1,529,182
Accrued interest, related parties							$ 4,770	3,570	1,170
Notes Payable, Related Parties [Member]
Accrued interest, related parties							4,770	3,570
Joint Venture Partner [Member]
Other receivable, related party							48,778
Chief Executive Officer [Member]
Reimbursable expenses							1,192	306	3,265
Unsecured loan											$ 10,000
Interest rate											8.00%
Chief Executive Officer [Member] | Notes Payable, Related Parties [Member]
Unsecured loan											$ 10,000
Board of Directors Chairman [Member]
Amount owed							46,016	46,016	37,486
Reimbursable expenses							$ 6,228	$ 6,167	$ 13,917
Unsecured loan											$ 10,000
Interest rate											8.00%
Stock issued, shares			1,000,000	4,000,000
Stock issued, value			$ 10	$ 40
Exercise price of warrants			$ 0.00001	$ 0.00001
Board of Directors Chairman [Member] | Notes Payable, Related Parties [Member]
Unsecured loan											$ 10,000
Board of Directors Chairman [Member] | Series A Preferred Stock [Member]
Stock issued, shares						1,000,000
Stock issued, value						$ 1,000
Exercise price of warrants						$ 0.001
Board of Directors Chairman [Member] | October 1, 2015 [Member]
Stock issued, shares								3,000,000
Stock issued, value								$ 30
Exercise price of warrants								$ 0.00001
Chief Executive Officer [Member]
Stock issued, shares				4,000,000
Stock issued, value				$ 40
Exercise price of warrants				$ 0.00001
Chief Executive Officer [Member] | Series A Preferred Stock [Member]
Stock issued, shares						1,000,000
Stock issued, value						$ 1,000
Exercise price of warrants						$ 0.001
Director [Member]
Unsecured loan											$ 10,000
Interest rate											8.00%
Director [Member] | Notes Payable, Related Parties [Member]
Unsecured loan											$ 10,000
Richard Najarian [Member]
Stock issued, shares					600,000
Stock issued, value					$ 13,765
Purchase shares of common stock	200,000	200,000
Common stock fair value					$ 9,120
Jay Rosen [Member]
Purchase shares of common stock	200,000	200,000
John Borza [Member]
Purchase shares of common stock	600,000	600,000
Heidi Carl [Member]
Purchase shares of common stock	750,000	750,000
Mitchell Felder [Member]
Purchase shares of common stock	1,000,000	1,000,000
William Hartman [Member]
Purchase shares of common stock										1,000,000

Fair Value of Financial Instr44

Fair Value of Financial Instruments (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Assets
Cash	$ 125,341	$ 22,437	$ 35,414
Liabilities
Convertible note payable, net of discounts		153,024	41,815
Notes payable, related parties
Derivative liabilities	6,253,880	221,822	150,076
Fair Value, Measurements, Recurring [Member] | Level 1 [Member]
Assets
Cash	125,341	22,437	35,414
Total assets	125,341	22,437	35,414
Liabilities
Convertible note payable, net of discounts
Notes payable, related parties
Derivative liabilities
Total liabilities
Net assets and liabilities	125,341	22,437	35,414
Fair Value, Measurements, Recurring [Member] | Level 2 [Member]
Assets
Cash
Total assets
Liabilities
Convertible note payable, net of discounts		153,024	41,815
Notes payable, related parties	30,000	30,000	30,000
Derivative liabilities
Total liabilities	30,000	183,024	71,815
Net assets and liabilities	(30,000)	(183,024)	(71,815)
Fair Value, Measurements, Recurring [Member] | Level 3 [Member]
Assets
Cash
Total assets
Liabilities
Convertible note payable, net of discounts
Notes payable, related parties
Derivative liabilities	6,253,880	221,822
Total liabilities	6,253,880
Net assets and liabilities	$ (6,253,880)

Joint Venture (Details Narrativ

Joint Venture (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016	Sep. 13, 2016	Oct. 07, 2015
Common stock warrants	1,250,000	1,250,000		3,750,000
Strike price	$ 0.05	$ 0.05
Capital contribution	$ 25,000	$ 25,000
Capital description	ATS will contribute (i) technical, labor, manufacturing information and know-how required to produce the initial product, an extended duration topical pain relief patch; (ii) $5,000 worth of primary ingredients; and (iii) $5,000 worth of other materials to produce the initial prototype pain relief patches.	ATS will contribute (i) technical, labor, manufacturing information and know-how required to produce the initial product, an extended duration topical pain relief patch; (ii) $5,000 worth of primary ingredients; and (iii) $5,000 worth of other materials to produce the initial prototype pain relief patches.
Equity in losses of investment in joint venture	$ (2,058)
Premier [Member]
Percentage of ownership in PBPMS			50.00%
Percentage of profit allocated from PBPMS			89.00%
ATS [Member]
Percentage of ownership in PBPMS			50.00%
Percentage of profit allocated from PBPMS			11.00%

Other Current Assets (Details)

Other Current Assets (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Other Current Assets Details
Deposit on inventory purchase	$ 52,100
Other receivable, related party	48,778
Prepaid expenses	17,743	11,430
Other current assets, Total	$ 141,521	$ 11,430

Convertible Notes Payable (Deta

Convertible Notes Payable (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Total convertible note payable		$ 302,480	$ 288,000
Less unamortized debt discounts: Derivative discounts		149,456	129,422
Less unamortized debt discounts: Discount on beneficial conversion feature			81,648
Less unamortized debt discounts: Original issue discount			13,164
Loan origination discounts			21,951
Convertible note		153,024	41,815
Less: current portion		153,024	41,815
Convertible note payable, less current portion
On October 10, 2016 Unserured loan [Member]
Total convertible note payable		275,000
On March 11, 2016 Unsecured loan [Member]
Total convertible note payable		27,480
On May 27, 2016 Unserured loan [Member]
Total convertible note payable
On March 07, 2016 Unsecured loan [Member]
Total convertible note payable
On February 24, 2016 Unsecured loan [Member]
Total convertible note payable
On January 8, 2016 Unsecured loan [Member]
Total convertible note payable
On December 28, 2015 Unsecured loan [Member]
Total convertible note payable			157,500
On December 15, 2015 Unsecured loan [Member]
Total convertible note payable			27,500
On September 21, 2015 Unsecured loan [Member]
Total convertible note payable			48,000
On September 2, 2015 Unsecured loan [Member]
Total convertible note payable			$ 55,000

Convertible Notes Payable (De48

Convertible Notes Payable (Details 1) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Convertible Notes Payable Details 1
Interest on judgment payable			$ 13,141
Interest on convertible notes	$ 2,691	$ 35,048	52,720	21,172
Interest on related party loans	1,200	1,200	2,400	1,170
Amortization of derivative discounts			551,149	578
Amortization of beneficial conversion feature		81,648	79,451	10,272
Amortization of OID		20,647	81,648	117,500
Amortization of loan origination costs		44,811	36,914	14,384
Derivative discounts	149,456	225,457
Amortization of warrants				32,973
Total interest expense	$ 152,747	$ 408,811	$ 817,423	$ 198,049

Convertible Notes Payable (De49

Convertible Notes Payable (Details 2) - USD ($)	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Derivative discounts		$ 149,456	$ 129,422
Beneficial conversion feature discounts			81,648
Original issue discounts			13,164
Loan origination costs			21,951
Total debt discounts		153,024	41,815
Interest Expense [Member]
Derivative discounts		571,183	130,000
Beneficial conversion feature discounts			167,011
Original issue discounts		23,750	21,037
Loan origination costs		57,500	28,750
Total debt discounts		$ 652,433	$ 346,798

Convertible Notes Payable (De50

Convertible Notes Payable (Details Narrative) - USD ($)

Oct. 10, 2016

Mar. 11, 2016

Mar. 07, 2016

Jan. 08, 2016

Dec. 15, 2015

Sep. 02, 2015

Nov. 21, 2016

May 27, 2016

Feb. 24, 2016

Dec. 28, 2015

Sep. 21, 2015

Dec. 31, 2016

Dec. 31, 2015

Debt discounts

$ 652,433

$ 346,798

Beneficial conversion feature of convertible note

167,011

Loan Origination Cost Discounts

57,500

28,750

Interest expense

$ 749,162

$ 175,707

Percentage of issued and outstanding shares

4.99%

Typenex [Member]

Converted shares

8,620,690

Converted amount

$ 25,000

November 21, 2016 and February 24, 2017 [Member] | Typenex [Member]

Converted shares

135,596,882

Converted amount

$ 300,000

Interest expense

8,750

Total

$ 308,750

Seventh Redwood Note [Member]

Interest rate

10.00%

Face value

$ 300,000

Maturity date

Oct. 10, 2017

Total amount paid

$ 300,000

Debt description

The principal and interest of the Seventh Redwood Note is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law.

Fifth Redwood Note [Member]

Interest rate

10.00%

Face value

$ 105,000

Maturity date

Dec. 11, 2016

Debt description

The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law.

Net proceeds

$ 90,000

Fifth Redwood Note [Member] | November 8, 2016 and December 22, 2016 [Member]

Converted shares

32,647,975

Converted amount

$ 77,520

Interest expense

3,550

Total

$ 81,070

Fifth Redwood Convertible Note | November 8, 2016 and March 13, 2017 [Member]

Converted shares

47,820,025

Converted amount

$ 105,000

Interest expense

15,517

Total

$ 120,517

First Redwood Note [Member]

Interest rate

10.00%

Face value

$ 157,500

Maturity date

Sep. 28, 2016

Debt description

The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law.

Net proceeds

$ 130,000

First Redwood Note [Member] | April 6, 2016 and December 7, 2016 [Member]

Converted shares

29,612,923

Converted amount

$ 157,500

Interest expense

6,507

Total

$ 164,007

Second Redwood Note [Member]

Interest rate

10.00%

Face value

$ 131,250

Maturity date

Oct. 8, 2016

Debt description

The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law.

Net proceeds

$ 107,500

Second Redwood Note [Member] | July 11, 2016 and August 1, 2016 [Member]

Converted shares

23,360,868

Converted amount

$ 131,250

Third Redwood Note [Member]

Interest rate

10.00%

Face value

$ 78,750

Maturity date

Nov. 22, 2016

Debt description

The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law.

Net proceeds

$ 67,500

Third Redwood Note [Member] | August 26, 2016 and December 7, 2016 [Member]

Converted shares

17,926,514

Converted amount

$ 78,750

Interest expense

4,607

Total

$ 83,357

Fourth Redwood Note [Member]

Interest rate

10.00%

Face value

$ 78,750

Maturity date

Dec. 7, 2016

Debt description

The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law.

Net proceeds

$ 67,500

Fourth Redwood Note [Member] | October 26, 2016 and December 7, 2016 [Member]

Converted shares

20,628,179

Converted amount

$ 78,750

Interest expense

5,180

Total

$ 83,930

Sixth Redwood Note [Member]

Interest rate

10.00%

Face value

$ 105,000

Maturity date

Feb. 27, 2017

Debt description

The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law.

Net proceeds

$ 85,000

Sixth Redwood Note [Member] | July 13, 2016 and December 7, 2016 [Member]

Converted shares

20,039,892

Converted amount

$ 105,000

Interest expense

1,879

Total

$ 106,879

First JMJ Note [Member]

Loan Origination Cost Discounts

$ 5,000

Interest rate

12.00%

Face value

$ 55,000

Maturity date

Sep. 1, 2016

Debt description

The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of sixty percent (60%) of the lowest trading price of the CompanyÂ’s common stock over the twenty five (25) trading days prior to the conversion request date, or a fixed rate of $0.00005 per share, as amended within the original promissory note on September 8, 2015 (In the case that conversion shares are not deliverable by DWAC an additional 10% discount will apply; and if the shares are ineligible for deposit into the DTC system and only eligible for Xclearing deposit an additional 5% discount shall apply; in the case of both an additional cumulative 15% discount shall apply)

Draw proceeds

$ 250,000

Net proceeds

$ 50,000

Percentage of issued and outstanding shares

4.99%

Common stock conversion basis

The Company reserved at least 24 million shares of common stock for potential conversions.

First JMJ Note [Member] | March 2, 2016 and April 19, 2016 [Member]

Converted shares

12,359,944

Converted amount

$ 55,000

Interest expense

7,222

Total

$ 62,222

First Vis Vires Note [Member]

Interest rate

8.00%

Face value

$ 48,000

Maturity date

Jun. 8, 2016

Debt description

The principal and interest was convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of fifty eight percent (58%) of the average of the three (3) lowest closing bid prices over the 10 days prior to conversion, or a fixed rate of $0.00001 per share. The note included various prepayment penalties ranging from 112% through 130%, and default provisions of 150% of the then outstanding principal and interest, and an interest rate of 22% thereafter.

Net proceeds

$ 45,000

Percentage of issued and outstanding shares

4.99%

Common stock conversion basis

The Company must at all times reserve at least 20,250,000 shares of common stock for potential conversions.

Second JMJ Note [Member]

Loan Origination Cost Discounts

$ 2,500

Interest rate

12.00%

Face value

$ 27,500

Maturity date

Dec. 15, 2016

Debt description

The principal and interest was convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of sixty percent (60%) of the lowest trading price of the CompanyÂ’s common stock over the twenty five (25) trading days prior to the conversion request date, or a fixed rate of $0.00005 per share, as amended within the original promissory note on September 8, 2015 (In the case that conversion shares are not deliverable by DWAC an additional 10% discount will apply; and if the shares are ineligible for deposit into the DTC system and only eligible for Xclearing deposit an additional 5% discount shall apply; in the case of both an additional cumulative 15% discount shall apply)

Draw proceeds

$ 250,000

Net proceeds

$ 25,000

Percentage of issued and outstanding shares

4.99%

Common stock conversion basis

The Company reserved at least 24 million shares of common stock for potential conversions.

Notes Payable, Related Partie51

Notes Payable, Related Parties (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Total notes payable, related parties	$ 30,000	$ 30,000	$ 30,000
Less: current portion	30,000	30,000	30,000
Notes payable, related parties, less current portion
Chief Executive Officer [Member]
Total notes payable, related parties	10,000	10,000	10,000
Board of Directors Chairman [Member]
Total notes payable, related parties	10,000	10,000	10,000
Director [Member]
Total notes payable, related parties	$ 10,000	$ 10,000	$ 10,000

Notes Payable, Related Partie52

Notes Payable, Related Parties (Details Narrative) - USD ($)	Jul. 06, 2015	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Accrued interest				$ 18,026	$ 7,792
Chief Executive Officer [Member]
Unsecured loan	$ 10,000
Board of Directors Chairman [Member]
Unsecured loan	10,000
Directors [Member]
Unsecured loan	10,000
Notes Payable, Related Parties [Member]
Interest expense		$ 1,200	$ 1,200	$ 2,400	$ 1,170
Notes Payable, Related Parties [Member] | Chief Executive Officer [Member]
Unsecured loan	$ 10,000
Interest rate	8.00%
Notes Payable, Related Parties [Member] | Board of Directors Chairman [Member]
Unsecured loan	$ 10,000
Interest rate	8.00%
Notes Payable, Related Parties [Member] | Directors [Member]
Unsecured loan	$ 10,000
Interest rate	8.00%

Derivative Liabilities (Details

Derivative Liabilities (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Derivative Liabilities Details
Beginning Balance	$ 221,822	$ 150,076
Increase in derivative value due to issuances of convertible promissory notes		583,415	144,748
Increase in derivative value due to issuances of warrants	7,103,444
Change in fair market value of derivative liabilities due to the mark to market adjustment	(842,343)	13,816	5,328
Debt conversions	(229,043)	(525,485)
Ending Balance	$ 6,253,880	$ 221,822	$ 150,076

Derivative Liabilities (Detai54

Derivative Liabilities (Details Narrative) - USD ($)	Oct. 07, 2015	Oct. 07, 2015	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Derivative liabilities			$ 6,253,880		$ 221,822	$ 150,076
Change in derivative liabilities			(6,261,101)	$ 87,862	(26,048)	(20,076)
Change in fair value in excess of convertible notes			4,945,782	12,232	12,232	14,748
Change in fair market value of derivative liabilities due to the mark to market adjustment			(842,343)		$ 13,816	$ 5,328
Change in fair market value of the warrants adjustment			147,088	$ 75,630
Change in fair market value on convertible notes adjustment			$ 7,221
Volatility	232.00%	232.00%
Maturity term			2 years		2 years	2 years
Warrant maturity date			Mar. 30, 2020
Increase in trading fees (monthly)			1.00%		1.00%	1.00%
Default event, Description			An event of default would occur -0-% of the time, increasing 1% per month to a maximum of 20%.		An event of default would occur -0-% of the time, increasing 1% per month to a maximum of 20%.	An event of default would occur -0-% of the time, increasing 1% per month to a maximum of 20%.
Fundamental transaction, Description			A change of control and fundamental transaction would occur initially -0-% of the time and increase monthly by -0-% to a maximum of -0-%.		A change of control and fundamental transaction would occur initially -0-% of the time and increase monthly by -0-% to a maximum of -0-%.	A change of control and fundamental transaction would occur initially -0-% of the time and increase monthly by -0-% to a maximum of -0-%.
Reset event, Description			Reset events were projected to occur by 12/31/17 and 12/31/18 ? the reset provision ends 3/30/19 and the option expires 3/30/20.
Minimum [Member]
Stock price			$ 0.0435		$ 0.0435	$ 0.0435
Volatility			145.00%		145.00%	145.00%
Trading fees (monthly)			$ 556,020		$ 556,020	$ 556,020
Minimum [Member] | Historical Annual Volatility [Member]
Volatility			261.86%
Maximum [Member]
Stock price			$ 0.0050		$ 0.0050	$ 0.0050
Volatility			385.00%		385.00%	385.00%
Trading fees (monthly)			$ 911,155		$ 911,155	$ 911,155
Maximum [Member] | Historical Annual Volatility [Member]
Volatility			261.99%

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Oct. 07, 2015	Oct. 07, 2015	May 09, 2012	Jul. 28, 2016	May 27, 2016	Dec. 13, 2016	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Agreement term	10 years	10 years						0 years	9 years 2 months 19 days
Common stock issued on equity line of credit, Amount								$ 143,520
Interest on judgment payable								13,141
Judgment payable								340,647
Gain on settlement of judgment								53,788
10% Convertible note issued in settlement of judgment payable								$ 300,000
Collaborative Patent License Agreements [Member]
Sales revenue gross			10.00%
Agreement term			5 years
Typenex Judgment [Member]
Judgment settlement amount				$ 340,647
Judgment award interest rate				22.00%
Judgment settlement expenses				$ 300,000
Stock Purchase Agreement [Member]
Purchase of common stock					$ 2,000,000
Purchase of common stock discount rate					20.00%
Stock purchase agreement, Description					common stock during the five (5) previous business days and in an amount of the lesser of (i) $150,000 or (ii) 100% of the average daily trading volume of our common stock in the ten (10) business days immediately preceding the date we give notice to Redwood.
Common stock issued on equity line of credit, Amount						$ 143,520
Common stock issued on equity line of credit, Shares						27,952,890

Stockholders Equity (Details Na

Stockholders Equity (Details Narrative) - USD ($)	Aug. 08, 2017	Jan. 10, 2017	Dec. 13, 2016	Nov. 14, 2016	Nov. 08, 2016	Aug. 12, 2016	Apr. 11, 2016	Mar. 02, 2016	Feb. 12, 2016	Feb. 10, 2016	Dec. 15, 2015	Dec. 08, 2015	Dec. 04, 2015	Dec. 02, 2015	Dec. 01, 2015	Nov. 12, 2015	Nov. 11, 2015	Nov. 09, 2015	Nov. 06, 2015	Nov. 02, 2015	Oct. 13, 2015	Oct. 08, 2015	Oct. 07, 2015	Oct. 07, 2015	Sep. 10, 2015	Sep. 03, 2015	Sep. 02, 2015	Aug. 12, 2015	Aug. 04, 2015	Jun. 03, 2015	May 30, 2017	Mar. 30, 2017	Feb. 13, 2017	Dec. 23, 2016	Nov. 22, 2016	Oct. 19, 2016	Jul. 21, 2016	Apr. 19, 2016	Mar. 28, 2016	Mar. 17, 2016	Jan. 29, 2016	Dec. 24, 2015	Nov. 25, 2015	Nov. 17, 2015	Nov. 16, 2015	Oct. 27, 2015	Oct. 26, 2015	Oct. 19, 2015	Sep. 21, 2015	Sep. 18, 2015	Aug. 26, 2015	Aug. 25, 2015	Aug. 17, 2015	Jul. 23, 2015	Jun. 25, 2015	Feb. 24, 2015	Jan. 30, 2015	Mar. 13, 2017	Jun. 30, 2017	Dec. 22, 2016	Dec. 31, 2016	Dec. 31, 2015
Preferred stock, par value																																																											$ 0.001		$ 0.001	$ 0.001
Preferred stock, authorized shares																																																											10,000,000		10,000,000	10,000,000
Exercise of preferred stock warrants at $0.001 per share, related parties, Amount																																																													$ 2,000
Common stock, par value										$ 0.00001																																																	$ 0.00001		$ 0.00001	$ 0.00001
Common stock, authorized shares																																																											1,000,000,000		1,000,000,000	1,000,000,000
Common stock issued on debt conversions, Amount																																																													$ 737,716	$ 227,388
Warrant exercise price																							$ 0.05	$ 0.05
Warrant exercisable term																							10 years
Common stock issued on equity line of credit, Amount																																																													143,520
Exercise of cashless warrants at $0.00001 per share, Amount
Shares issued for serttlement of reimbursements, related party, Amount																																																													13,765
Exercise of warrants at $0.00001 per share, related party, Amount																																																													200	40
Debt discount																																																											$ 149,456		$ 749,162	$ 175,707
Interest rate																							1.75%	1.75%																																						1.75%
Convertible note																																																													$ 153,024	$ 41,815
Series A Preferred Stock [Member]
Preferred stock, par value																																																													$ 0.001
Preferred stock, authorized shares																																																													2,000,000
Series A Preferred Stock voting right																																																													100 votes per share
Third Party [Member]
Fair value of common stock									$ 10,800
Common stock issued to a third-party for services, Amount				$ 11,821
Common stock issued to a third-party for services, Shares				2,626,867					600,000
Mr. Najarian [Member]
Fair value of common stock																																							$ 9,120
Shares issued for serttlement of reimbursements, related party, Amount																																							$ 13,765
Shares issued for serttlement of reimbursements, related party, Shares																																							600,000
Chairman, Board of Directors [Member]
Exercise of warrants at $0.00001 per share, related party, Amount																									$ 10
Exercise of warrants at $0.00001 per share, related party, Shares																									1,000,000
Chairman, Board of Directors [Member] | October 1, 2015 [Member]
Exercise of warrants at $0.00001 per share, related party, Amount																																																													$ 30
Exercise of warrants at $0.00001 per share, related party, Shares																																																													3,000,000
Chief Executive Officer [Member] | Preferred Stock Issuances for Exercise of Preferred Stock Warrants, Related Parties [Member]
Exercise of preferred stock warrants at $0.001 per share, related parties, Amount																																									$ 1,000
Exercise of preferred stock warrants at $0.001 per share, related parties, Shares																																									1,000,000
Chief Executive Officer [Member] | Series A Preferred Stock [Member]
Preferred stock, par value																																									$ 0.001
Board of Directors Chairman [Member] | Preferred Stock Issuances for Exercise of Preferred Stock Warrants, Related Parties [Member]
Exercise of preferred stock warrants at $0.001 per share, related parties, Amount																																									$ 1,000
Exercise of preferred stock warrants at $0.001 per share, related parties, Shares																																									1,000,000
Board of Directors Chairman [Member] | Series A Preferred Stock [Member]
Preferred stock, par value																																									$ 0.001
Cancellation [Member]
Common stock cancelled, Shares																												150,000
Exercise of Common Stock Warrants [Member]
Exercise of cashless warrants at $0.00001 per share, Shares										2,248,846
Cashless exercise of common stock warrants exercised shares										2,250,000
Exercise of Common Stock Warrants [Member] | Chief Executive Officer [Member]
Exercise of cashless warrants at $0.00001 per share, Amount																																		$ 60		$ 40
Exercise of cashless warrants at $0.00001 per share, Shares																																		6,000,000		4,000,000
Exercise of Common Stock Warrants [Member] | Board of Directors Chairman [Member]
Exercise of cashless warrants at $0.00001 per share, Amount																																		$ 60		$ 40
Exercise of cashless warrants at $0.00001 per share, Shares																																		6,000,000		4,000,000
Securities Purchase Agreement [Member] | Third Closing [Member]
Aggregate amount	$ 150,000
Trading days of common stock	15 days
Traded price of Common stock	50.00%
Interest rate	8.00%
Securities Purchase Agreement [Member]
Aggregate amount																																$ 300,000
Deferred offering costs																																$ 15,000
Exchange shares of common stock																															30,303,033	40,000,002
Warrant exercisable term																															3 years	3 years
Effective reset provision, Description																																purchase price of the common stock of each tranche to the lower of (i) $0.02 or (ii) a 50% discount to the average of the three lowest closing prices in the 20 trading days prior to the reset date, which is the earlier of (i) the 7 month anniversary of the closing of each tranche of this transaction or (ii) 20 trading days after the effectiveness of each tranche.
Additional shares of common stock and warrant purchase																															$ 150,000	$ 150,000
Purchase price per share, Description																															Second Closing was the lesser of (i) $0.02, subject to certain adjustments for stock splits and other similar transactions, or (ii) 50% of the closing price on the trading day immediately prior to the date of sale.	Second Closing and Third Closing will be the lesser of (i) $0.02, subject to certain adjustments for stock splits and other similar transactions, or (ii) 50% of the closing price on the trading day immediately prior to the date of sale.
Securities Purchase Agreement [Member] | Second Closing [Member]
Aggregate amount	$ 150,000
Exchange shares of common stock	10,101,011
Trading days of common stock	15 days
Traded price of Common stock	50.00%
Maturity date	Nov. 30, 2017
Interest rate	8.00%
Convertible note	$ 50,000
Securities Purchase Agreement [Member] | Series A Warrants[Member]
Warrant purchase																															30,303,033	40,000,002
Warrant exercise price																															$ 0.03	$ 0.03
Securities Purchase Agreement [Member] | Series A Warrants[Member] | First Closing [Member]
Exchange shares of common stock	13,333,334
Securities Purchase Agreement [Member] | Series B Warrants [Member]
Warrant purchase																															30,303,033	40,000,002
Warrant exercise price																															$ 0.05	$ 0.05
Securities Purchase Agreement [Member] | Series B Warrants [Member] | First Closing [Member]
Exchange shares of common stock	13,333,334
First LG Capital Note [Member]
Common stock issued on debt conversions, Shares											1,762,516	2,794,392	1,526,070	3,022,017			2,259,167		1,979,568		1,076,992								292,181														3,003,665	2,261,963			1,620,522			681,800	446,711		371,556
Principal amount											$ 15,000	$ 16,946	$ 3,054	$ 4,860			$ 3,500		$ 3,070		$ 4,000								$ 3,687														$ 4,640	$ 3,500			$ 3,430			$ 6,000	$ 6,000		$ 5,000
Accured Interest											$ 1,039	$ 1,148	$ 204	$ 323			$ 216		$ 186		$ 222								$ 148														$ 301	$ 221			$ 200			$ 300	$ 270		$ 215
First LG Capital Note [Member] | Promissory note [Member]
Debt discount																																																									$ 32,143
Conversion price																																																									$ 0.042
Market price																																																									$ 0.14
First Adar Bay Note [Member]
Common stock issued on debt conversions, Shares																2,400,940	2,375,275	2,375,000		2,168,067		1,116,799				459,242																				1,839,530	1,753,425	1,284,109
Principal amount																$ 2,115
Accured Interest																$ 2,255
First Adar Bay Note [Member] | Promissory note [Member]
Debt discount																																																								$ 20,420
Conversion price																																																								$ 0.0473
Market price																																																								$ 0.14
JMJ Financial [Member] | Promissory note [Member]
Debt discount																											$ 50,000															$ 25,000
Conversion price																											$ 0.0194															$ 0.03262
Market price																											$ 0.032															$ 0.034
Vis Vires Group, Inc [Member] | Promissory note [Member]
Debt discount																																																	$ 39,448
Conversion price																																																	$ 0.00747
Market price																																																	$ 0.016
First Typenex Note [Member]
Common stock issued on debt conversions, Shares															4,441,702			3,510,000												172,812															3,000,000		3,091,128					823,121		260,866	208,719
Principal amount															$ 559
Accured Interest															$ 6,854
First Typenex Note [Member] | October 1, 2015 [Member]
Common stock issued on debt conversions, Shares																																																													2,344,032
Redwood Fund III, Ltd One [Member]
Common stock issued for debt financing, Shares										2,400,000
Fair value of common stock										$ 38,400
Redwood Fund III, Ltd [Member]
Common stock issued for debt financing, Shares										600,000
Fair value of common stock										$ 9,600
Redwood Convertible Note
Common stock issued on debt conversions, Shares																																																										142,148,242		152,837,041
Common stock issued on debt conversions, Amount																																																										$ 323,197
Principal amount																																																										302,480		$ 653,771
Accured Interest																																																										$ 20,717		$ 21,723
Common stock issued on equity line of credit, Amount		$ 10,323	$ 25,000		$ 25,000	$ 39,520																											$ 8,000		$ 25,000		$ 29,000
Common stock issued on equity line of credit, Shares		3,147,110	6,250,000		6,097,561	5,200,000																											2,000,000		6,377,551		4,027,778
First JMJ Note [Member]
Common stock issued on debt conversions, Shares							2,800,000	2,000,000																														3,159,944		4,400,000

Series A Convertible Preferre57

Series A Convertible Preferred Stock Warrants (Details ) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Warrants granted weighted average exercise price		$ 0.0784
Warrants exercisable weighted average exercise price, Ending balance	$ 0.96	$ 0.25
Series A Preferred Stock [Member]
Warrants outstanding, Beginning balance	2,000,000
Warrants expired
Warrants granted
Warrants exercised	(2,000,000)
Warrant outstanding, Ending balancre		2,000,000
Exercisable
Warrants outstanding weighted average exercise price, Beginning balance	$ 0.001
Warrants expired weighted average exercise price
Warrants granted weighted average exercise price
Warrants exercised weighted average exercise price	(0.001)
Warrants outstanding weighted average exercise price, Ending balance		$ 0.001
Warrants exercisable weighted average exercise price, Ending balance
Series A Preferred Stock [Member]
Warrants outstanding, Beginning balance	2,000,000	2,000,000
Warrants expired
Warrants granted
Warrants exercised
Warrant outstanding, Ending balancre		2,000,000
Warrants outstanding weighted average exercise price, Beginning balance	$ 0.001	$ 0.001
Warrants expired weighted average exercise price
Warrants granted weighted average exercise price
Warrants exercised weighted average exercise price
Warrants outstanding weighted average exercise price, Ending balance		$ 0.001

Series A Convertible Preferre58

Series A Convertible Preferred Stock Warrants (Details Narrative ) - USD ($)	1 Months Ended
	Jan. 29, 2016	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Preferred Stock, Shares Issued		2,000,000	2,000,000	0
Preferred stock, par value		$ 0.001	$ 0.001	$ 0.001
Series A Preferred Stock [Member]
Preferred stock, par value			$ 0.001
Series A Preferred Stock [Member] | Chief Executive Officer [Member]
Preferred Stock, Shares Issued	1,000,000
Preferred stock, par value	$ 0.001
Proceeds from preferred stock	$ 1,000
Series A Preferred Stock [Member] | Board of Directors Chairman [Member]
Preferred Stock, Shares Issued	1,000,000
Preferred stock, par value	$ 0.001
Proceeds from preferred stock	$ 1,000

Common Stock Warrants (Details)

Common Stock Warrants (Details) - Common Stock Warrants [Member]	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Shares Underlying Warrants Outstanding | shares	30,690,000
Weighted Average Remaining Contractual Life	4 years 10 months 28 days
Weighted Average Excercise Price	$ 0.24407
Shares Underlying Warrants Exercisable | shares	30,690,000
Weighted Average Exercise Price	$ 0.24407
Minimum [Member]
Range of Exercise Prices	0.00001
Maximum [Member]
Range of Exercise Prices	$ 1.45

Common Stock Warrants (Details

Common Stock Warrants (Details 1)	Oct. 07, 2015	Oct. 07, 2015	Dec. 31, 2016	Dec. 31, 2015
Common Stock Warrants Details 1
Average risk-free interest rates	1.75%	1.75%		1.75%
Average expected life (in years)	10 years	10 years	0 years	9 years 2 months 19 days

Common Stock Warrants (Detail61

Common Stock Warrants (Details 2) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Warrants expired weighted average exercise price		$ 0.0784
Warrants exercisable weighted average exercise price, Ending balance	$ 0.96	$ 0.25
Common Stock Warrants [Member]
Warrants outstanding, Beginning balance	53,591,455	50,591,455
Warrants expired	(351,455)	(50,000)
Warrants granted	(300,000)	7,050,000
Warrants exercised	(22,250,000)	(4,000,000)
Warrant outstanding, Ending balancre	30,690,000	53,591,455
Exercisable	30,690,000
Warrants outstanding weighted average exercise price, Beginning balance	$ 0.1463	$ 0.1443
Warrants cancelled weighted average exercise price	(0.18)	(0.25)
Warrants expired weighted average exercise price	(0.96)	0.0784
Warrants exercised weighted average exercise price	(0.00001)	(0.00001)
Warrants outstanding weighted average exercise price, Ending balance	0.24407	$ 0.1463
Warrants exercisable weighted average exercise price, Ending balance	$ 0.24407

Common Stock Warrants (Detail62

Common Stock Warrants (Details Narrative) - USD ($)	Oct. 07, 2015	Oct. 07, 2015	Jul. 25, 2015	Apr. 30, 2015	Mar. 20, 2015	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 23, 2016	Oct. 19, 2016	Feb. 10, 2016	Sep. 10, 2015
Warrants to purchase common shares		3,750,000
Exercise price		$ 0.05
Warrant exercisable term		10 years
Fair value of common stock warrants		$ 31,109
Fair value per share		$ 0.0083
Volatility rate	232.00%	232.00%
Risk-free interest rate	1.75%	1.75%						1.75%
Expected term	10 years	10 years					0 years	9 years 2 months 19 days
Professional fee						$ 86,756	$ 332,650	$ 2,015,898
Cancelled common shares							351,455
Cancelled common shares description							(i) $0.18, and (ii) 70% of the Market Price, which is the average of the three (3) lowest VWAPs, not less than a fixed floor of $0.0001, during the twenty (20) trading day period ending on the last complete trading day prior to the date the conversion notice is delivered, or 65% if that price is less than $0.10 per share was cancelled during the year ended December 31, 2016 pursuant to the settlement reached with Typenex
Warrants Exercisable							300,000	50,000
Warrants exercisable price							$ 0.96	$ 0.25
Common shares issued											2,248,846
Cashless exercise warrants											2,250,000
Common stock, par value						$ 0.00001	$ 0.00001	0.00001			$ 0.00001
Warrants expired weighted average exercise price								$ 0.0784
Common Stock Warrants [Member]
Professional fee							$ 25,030	$ 6,079
Warrants exercisable price							$ 0.24407
Warrants expired weighted average exercise price							$ (0.96)	$ 0.0784
Richard Najarian [Member]
Warrants to purchase common shares		200,000
Jay Rosen [Member]
Warrants to purchase common shares		200,000
Independent contractor One [Member]
Professional fee							$ 39,769	$ 1,849,169
Professional fee related to related party							25,030	1,529,182
Independent contractor [Member]
Warrants to purchase common shares			500,000	500,000	500,000
Exercise price			$ 0.10	$ 0.25	$ 0.20
Warrant exercisable term			7 years	7 years	5 years
Fair value of common stock warrants			$ 4,720	$ 4,706
Fair value per share			$ 0.0094	$ 0.0094
Volatility rate			232.00%	232.00%
Risk-free interest rate			1.75%	1.75%	204.00%
Expected term			7 years	7 years
Professional fee							0	11,943
Call option value, per share			$ 0.0497	$ 0.13751	$ 0.1166
Total call option value			$ 24,872	$ 68,756	$ 58,301
Stock based compensation expense					$ 58,301
Independent contractor [Member] | Common Stock Warrant [Member]
Warrants to purchase common shares					125,000
Exercise price					$ 0.20
Independent contractor [Member] | Common Stock Warrant One [Member]
Warrants to purchase common shares					125,000
Exercise price					$ 0.30
Independent contractor [Member] | Common Stock Warrant Two [Member]
Warrants to purchase common shares					125,000
Exercise price					$ 0.40
Independent contractor [Member] | Common Stock Warrant Three [Member]
Warrants to purchase common shares					125,000
Exercise price					$ 0.50
Scientific Advisory Board [Member]
Warrants to purchase common shares		1,800,000
Exercise price		$ 0.05
Warrant exercisable term		10 years
Fair value of common stock warrants		$ 14,931
Fair value per share		$ 0.0083
Volatility rate		232.00%
Risk-free interest rate		1.75%
Expected term		10 years
Professional fee							$ 14,739	$ 14,421
William Hartman [Member]
Warrants to purchase common shares		1,000,000
Mitchell Felder [Member]
Warrants to purchase common shares		1,000,000
Heidi Carl [Member]
Warrants to purchase common shares		750,000
John Borza [Member]
Warrants to purchase common shares		600,000
Board of Directors Chairman [Member]
Common shares issued									6,000,000	4,000,000		1,000,000
Common stock, par value									$ 0.00001	$ 0.00001		$ 0.00001
Proceeds from issuance									$ 60	$ 40		$ 10
Board of Directors Chairman [Member] | October 1, 2015 [Member]
Common shares issued							3,000,000
Common stock, par value							$ 0.00001
Proceeds from issuance							$ 30
Chief Executive Officer [Member]
Common shares issued									6,000,000	4,000,000
Common stock, par value									$ 0.00001	$ 0.00001
Proceeds from issuance									$ 60	$ 40

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating loss carry forwards	$ 1,629,600	$ 1,516,900	$ 932,050
Net deferred tax assets before valuation allowance	1,629,600	1,516,900	932,050
Less: Valuation allowance	(1,629,600)	(1,516,900)	(932,050)
Net deferred tax assets

Income Taxes (Details 1)

Income Taxes (Details 1)	6 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2017	Sep. 30, 2015	Dec. 31, 2016
Income Taxes Details 1
Federal and state statutory rate	35.00%	35.00%	35.00%
Change in valuation allowance on deferred tax assets	(35.00%)	(35.00%)	(35.00%)

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Taxes Details Narrative
Federal net operating losses	$ 4,656,000	$ 4,334,000	$ 2,663,000
Federal net operating losses expire	2,031	2,031

Subsequent Events (Narrative)

Subsequent Events (Narrative) - USD ($)

Aug. 08, 2017

Oct. 07, 2015

Oct. 07, 2015

May 30, 2017

Mar. 30, 2017

Mar. 13, 2017

Mar. 30, 2017

Dec. 31, 2016

Dec. 31, 2015

Jun. 30, 2017

Feb. 13, 2017

Jan. 10, 2017

Warrants to purchase common shares

3,750,000

Exercise price

$ 0.05

Warrant exercisable term

10 years

Interest amount

$ 749,162

$ 175,707

Common stock, issued shares

304,556,650

82,331,062

522,155,037

Interest rate

1.75%

1.75%

1.75%

Convertible note

$ 153,024

$ 41,815

Subsequent Event [Member]

Common Stock Issued for Debt Conversion, shares

142,148,242

Common Stock Issued for Debt Conversion, value

$ 323,197

Principal debt amount

302,480

Interest amount

$ 20,717

Securities Purchase Agreement [Member]

Warrant exercisable term

3 years

3 years

Aggregate amount

$ 300,000

$ 300,000

Securities Purchase Agreement [Member] | Subsequent Event [Member]

Exchange shares of common stock

40,000,002

40,000,002

Proceeds from exchange shares

$ 300,000

$ 300,000

Additional shares of our common stock and warrants value

$ 150,000

$ 150,000

Per share purchase price description

(i) $0.02, subject to certain adjustments for stock splits and other similar transactions, or (ii) 50% of the closing price on the trading day immediately prior to the date of sale

Beneficial ownership percentage

9.99%

9.99%

Common stock, issued shares

2,000,000

3,147,110

Draw down amount

$ 8,000

$ 10,323

Securities Purchase Agreement [Member] | Subsequent Event [Member] | Series A Warrants[Member]

Warrants to purchase common shares

40,000,002

Exercise price

$ 0.03

Warrant exercisable term

3 years

Securities Purchase Agreement [Member] | Subsequent Event [Member] | Series B Warrants [Member]

Warrants to purchase common shares

40,000,002

Exercise price

$ 0.05

Warrant exercisable term

3 years

Second Closing [Member] | Securities Purchase Agreement [Member]

Exchange shares of common stock

10,101,011

Trading days of common stock

15 days

Traded price of Common stock

50.00%

Maturity date

Nov. 30, 2017

Interest rate

8.00%

Convertible note

$ 50,000

Aggregate amount

$ 150,000

Series A Warrants[Member] | First Closing [Member] | Securities Purchase Agreement [Member]

Exchange shares of common stock

13,333,334

Series B Warrants [Member] | First Closing [Member] | Securities Purchase Agreement [Member]

Exchange shares of common stock

13,333,334